EP4164551A1 - Matériau textile pour dispositifs médicaux - Google Patents

Matériau textile pour dispositifs médicaux

Info

Publication number
EP4164551A1
EP4164551A1 EP20753484.3A EP20753484A EP4164551A1 EP 4164551 A1 EP4164551 A1 EP 4164551A1 EP 20753484 A EP20753484 A EP 20753484A EP 4164551 A1 EP4164551 A1 EP 4164551A1
Authority
EP
European Patent Office
Prior art keywords
fabric
leaflet
polymer
stent
cuff
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20753484.3A
Other languages
German (de)
English (en)
Inventor
Yousef F. Alkhatib
Jay REIMER
Paul E. Ashworth
Keith T. HIGH
Richard Kaleta
Ryan Finn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of EP4164551A1 publication Critical patent/EP4164551A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00—Products made by additive manufacturing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0076—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof multilayered, e.g. laminated structures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0015—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in density or specific weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0015—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in density or specific weight
    • A61F2250/0017—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in density or specific weight differing in yarn density
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0018—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in elasticity, stiffness or compressibility
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0023—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in porosity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0028—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in fibre orientations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0036—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in thickness
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0051—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in tissue ingrowth capacity, e.g. made from both ingrowth-promoting and ingrowth-preventing parts

Definitions

  • the present disclosure relates to synthetic fabric materials that can be used in various medical devices and the medical devices including the synthetic fabric materials.
  • prosthetic heart valves and particularly collapsible/expandable prosthetic heart valves useful for delivery through a catheter or trocar, will be exemplified.
  • Prosthetic heart valves including surgical heart valves and collapsible/expandable heart valves intended for transcatheter aortic valve replacement (“TAVR”) or transcatheter mitral valve replacement (“TMVR”), are well known in the patent literature.
  • TAVR transcatheter aortic valve replacement
  • TMVR transcatheter mitral valve replacement
  • Surgical or mechanical heart valves may be sutured into a native annulus of a patient during an open-heart surgical procedure, for example.
  • Collapsible/expandable heart valves may be delivered into a patient via a tube-like delivery apparatus such as a catheter, a trocar, a laparoscopic instrument, or the like to avoid a more invasive procedure such as full open-chest, open-heart surgery.
  • a “collapsible/expandable” heart valve includes heart valves that are formed with a small cross-section that enables them to be delivered into a patient through a tube-like delivery apparatus in a minimally invasive procedure, and then expanded to an operable once in place, as well as heart valves that, after construction, are first collapsed to a small cross-section for delivery into a patient and then expanded to an operable size once in place.
  • Collapsible/expandable prosthetic heart valves typically take the form of a one-way valve structure (often referred to herein as a valve assembly) mounted to/within an expandable stent.
  • these collapsible/expandable heart valves include a self-expanding or balloon-expandable stent, often made of nitinol or steel.
  • the one-way valve assembly mounted to/within the stent includes one or more leaflets, and may also include a cuff or skirt. The cuff may be disposed on the stent’ s interior or luminal surface, its exterior or abluminal surface, and/or on both surfaces.
  • a cuff ensures that blood does not just flow around the valve leaflets if the valve or valve assembly are not optimally seated in a valve annulus.
  • a cuff, or a portion of a cuff disposed on the exterior of the stent, can help retard leakage around the outside of the valve (the latter known as paravalvular leakage or “PV” leakage).
  • Leaflets, cuffs and valve assemblies for prosthetic heart valves may be derived from various natural tissues or synthetic materials. Commercial natural tissues that have been chemically treated or “fixed” are often used. For example, leaflets could be made of bovine pericardium and cuffs could be made of porcine pericardium. (See, e.g., U.S. Patent Nos. 5,957,949 at 6:23-33; 6,458,153 at 8:28-40; 5,855,601 at 6:21-30; and 7,585,321 at 13:5-36.) Other materials that may be used include various synthetic polymers including, without limitation, polytetrafluoroethylene (PTFE) or polyester (see U.S. Patent Nos.
  • PTFE polytetrafluoroethylene
  • Valve components and valve assemblies may be attached to a collapsible/expandable stent or frame by sutures or may be molded, glued, or soldered to the stent. ( See U.S. Patent No. 7,585,321 at 13:30-31.)
  • the disclosure describes polymer-containing fabric materials that may be used for construction of medical devices including, without limitation: venous valves, occluders, prosthetic vascular conduits, grafts, and embolic protection devices, fabrics for treating hernias, skin patches, vaginal patches, cardiac patches, adhesion barriers, surgical heart valves (those requiring open chest surgery to implant) and collapsible/expandable prosthetic heart valves which can be implanted using a catheter such as trans- femorally, trans-apically, and trans-septally.
  • the disclosure also describes and contemplates the medical devices made using these polymer-containing fabric materials as well as methods of making the fabric materials and the medical devices.
  • the polymeric fabric materials include uncoated fabrics and coated fabrics. Fabrics are made from interlaced fibers and include, inter alia, woven fabrics, knitted fabrics, felts, other non-woven mats and the like.
  • the fabric materials described herein include at least some synthetic fibers, such as, for example, fibers made from polyolefins such as polytetrafluoroethylene (PTFE) (which includes expanded and stretched PTFE and PTFE of any molecular weight) (also known as Teflon ® ), polyethylenes including those of any molecular weight (e.g., ultra-high molecular weight polyethylene (UHMWPE)), and polypropylenes including those of any molecular weight (e.g., ultra-high molecular weight polypropylene (UHMWPP), as well as polyurethanes, PEEK, polyvinyl alcohols, silicones, rayons, polyesters, aramids, spandex, or combinations, blends and copolymers thereof.
  • the uncoated fabric may have at least one of the following properties: a thread count of at least about 150 fibers per square inch, and the thread count need not be symmetrical; a high density weave of generally at least 300 fibers or more per square inch; a tensile strength of at least 50N and in some embodiments, 100 N or more; and/or an areal density of between 0.5 and 1.3 ounces/yard 2 (the areal density being the mass of the fabric per square yard).
  • the uncoated fabric may have a thickness of between about 10 pm and about 200 pm.
  • the fabric may also control (facilitate or retard) cell attachment and proliferation.
  • the polymeric fabric may be coated with at least one polymer layer to form a coated fabric.
  • Coated as used herein means that the fabric has a polymer applied to at least a portion of it after the fabric has otherwise been formed. Coatings may be formed of a single polymer layer, multiple polymer layers, and/or patterns of discrete polymer layers on one or more surfaces of the fabric. Where multiple polymer coatings are used, they may be the same or different in terms of thickness, composition, number of layers and/or location. In some embodiments, the polymer coating may provide improved or altered properties to the fabric relative to the uncoated fabric.
  • altered properties may include, without limitation, one or more of: (1) adjusting the porosity of the fabric, (2) adjusting surface roughness, (3) altering strength, abrasion resistance, and/or flexibility, (4) altering lubricity, (5) providing weight or rigidity to portions of the fabric, (6) promoting folding in specific regions, (7) altering cell adhesion to the fabric, and (8) retention or release of a therapeutic agent.
  • the polymers which may be used for the coatings include all of those previously identified for use for the fabric.
  • the polymer coating can be bioabsorbable, biodegradable, and/or bio-erodible.
  • Exemplary bioabsorbable, biodegradable, and/or bio-erodible polymers may include poly-glycolic acid, poly-L-Iactic acid, copolymers of poly-glycolic acid, poly-L-Iactic acid, polycaprolactone, poly-DL lactic acid, polytrimethylene carbonate, polydioxanone, poliglecaprone and polyglactin.
  • Such bioabsorbable, biodegradable, and/or bio-erodible polymers may be provided as a coating on a surface in a thickness sufficient to delay tissue growth on the coated surface.
  • a single polymer coating layer may be used on one major surface of a fabric layer or multiple layers of the same or different polymer materials may be used on both major surfaces. Indeed, up to about 20 layers may be used on any surface or edge of the fabric. The total thickness of all such coatings can range from a minimum of about 0.50 pm to a maximum of about 100 pm per side of the fabric.
  • the coating may also be a partial coating and/or a contoured coating.
  • Partially coated means that some portion of a major surface or edge is uncoated while other portions are coated.
  • Contoured surfaces may be coated completely, but to different thicknesses or degrees. Either or both may be used to provide specific structural features to a side or edge of a coated fabric, to provide different patterns, and the like. Partial coatings may alter flexibility, provide extra resistance against wear from contact, can add weight, can help maintain a desired shape, can help prevent fraying or unravelling of the fabric, facilitate attachment, add strength, etc., to a localized area of the fabric and any structure made from that fabric.
  • Coated (including partially coated) and uncoated fabrics may be provided with grommets to facilitate attachment while reducing damage that can come from the use of, for example, sutures.
  • Coated and uncoated fabrics may also be constructed with indicia to assist in placement or confirming operability during surgery. Structures made from uncoated fabrics, coated fabrics, and partially coated fabrics include, without limitation: the elements of a valve assembly used in a collapsible/expandable heart valve such as interior cuffs, exterior cuffs, and leaflets.
  • leaflets, cuffs or other structures may be reinforced, weighted, or have their flexibilities altered by the addition of other features, with or without coatings.
  • a row of sutures could be added, of varying number of stiches, in a line or other desired shape, across the full length of the structure or any portion thereof.
  • the properties can be altered based on the number and density of stiches, the number of sutures applied and the pattern in which they are applied. For example, by using one or more sutures extending from an attachment edge to a free edge of a leaflet, alternating stiffening and more flexible zones or “hinges” can be created.
  • a suture could also be stitched to at least a portion of the attachment edge and/or the free edge of a leaflet to provide reinforcement and/or weight and/or to introduce or preserve a shape.
  • localized portions of denser weaves can be used for the same purposes - at the attachment edge, the free edge, and/or across at least a portion of a major surface of the leaflet.
  • wires such as a steel or nitinol wire could be used and inserted into the weave along the attachment edge, the free edge or across a major surface of a leaflet, for example.
  • Wires or sutures or other structures could also be applied by gluing, laminating, etc. to a coated or uncoated fabric of the invention.
  • a wire could be disposed between a fabric material and a coating or layer laminated thereto at the free edge of a leaflet.
  • the wire or other reinforcement may extend across the entire edge, just a portion of it, and may be continuous or discontinuous.
  • the medical device or an element thereof such as a fabric leaflet, could be constructed or attached so as to form a pleat or fold across a major surface thereof.
  • Another embodiment of the disclosure provides a method of manufacturing a collapsible/expandable valve prosthesis that includes providing an uncoated polymeric fabric as just discussed having a top surface and a bottom surface (first and second major surfaces); providing a polymer such as, without limitation, an ultra-high molecular weight polyolefin; and applying the polymer to the top surface and/or the bottom surface of the fabric to form a coated fabric.
  • This application process may form the layer directly on the fabric or involve the application of a pre-prepared film to the fabric.
  • one or more polymer films may be laminated to one or more surfaces of a fabric by gluing or the application of heat and/or pressure.
  • a polymer layer may also be formed on the fabric by applying a liquid polymer material to a surface of the fabric and allowing it to solidify, cross-link, or otherwise become an adhered layer. This may be done by, for example, spray coating a polymer on one or more sides of the fabric, dip coating the fabric, and the like. Other techniques for applying the polymer coating include, for example, 3D printing. Partial coatings may be applied to a limited portion of the fabric as just discussed or may be formed by applying a complete coating to the fabric and removing portions by, for example, ablation. [0016] The fabric and any medical device made using that fabric may undergo sterilization. This may be done with a variety of sterilization modalities, for example, with ethylene oxide, peracetic acid, nitrogen oxide, e-beam, steam, gamma radiation, carbon dioxide and chemical liquid sterilant.
  • valve components and valve assemblies may be used. These include mechanical methods, for example cutting with scissors or a blade. Other techniques include, for example, cautery; stamping; chemical, laser, ultrasonic, or water jet cutting, bio-glue, folding or lamination.
  • One embodiment of a useful coated, partially coated or uncoated fabric is a high density weave of a polyethylene, a polypropylene or a PTFE, or blends or copolymers thereof, the fabric having a thread count of 300-500 x 100-300 fibers per square inch, a tensile strength of at least 65N, an areal density of at least 0.65 ⁇ 0.1 ounces/yard 2 , and a thickness of approximately 50-100 pm.
  • a useful coated, partially coated or uncoated fabric is a high density weave of UHMWPE, UHMWPP or UHMWPTFE, or blends or copolymers thereof, the fabric having a thread count of 300-500 x 100-300 fibers per square inch, a tensile strength of at least 65N, an areal density of at least 0.5 ⁇ 0.1 ounces/yard 2 , and a thickness of approximately 20-200 pm.
  • a useful coated, partially or uncoated fabric is a high density weave of ultra-high molecular weight polyethylene having a thread count of 440 x 220 fibers per square inch.
  • the uncoated fabric has a tensile strength of at least about 75N, an areal density of at least 0.65 0.1 ounces/yard 2 , and a maximum thickness of approximately 50-100 pm.
  • a useful coated, partially coated or uncoated fabric is a high density weave of ultra-high molecular weight polyethylene having a thread count of 440 x 220 fibers per square inch.
  • the uncoated fabric has a tensile strength of at least about 75N, an areal density of at least 0.5 0.05 ounces/yard 2 , and a thickness of approximately 50-100 pm.
  • a useful coated, partially coated or uncoated fabric is a high density weave of ultra-high molecular weight polyethylene having a thread count of 300-500 x 100-300 fibers per square inch.
  • the uncoated fabric has a tensile strength of at least 75N, an areal density of about 0.8 ⁇ 0.05 ounces/yard 2 , and a thickness of approximately 76 pm.
  • a useful coated, partially coated or uncoated fabric is a high density weave of ultra-high molecular weight polyethylene having a thread count of 440 x 220 fibers per square inch.
  • the uncoated fabric has a tensile strength of at least about 75N, an areal density of at least 0.65 ⁇ 0.05 ounces/yard 2 , and a thickness of approximately 50 pm.
  • a useful coated or partially coated fabric is a high density weave of PE or PTFE having a thread count of 300-500 x 100-300 fibers per square inch.
  • the uncoated fabric has a tensile strength of at least about 75N, an areal density of at least 0.65 ⁇ 0.05 ounces/yard 2 , and a thickness of approximately 250 pm or less.
  • the final or finished fabric material used in a medical device as described herein will have a thickness of between about 1 pm and about 1,000 pm and in some embodiments, between about 1 pm and about 500 pm and in still others, between about 5 pm and about 300 pm. It also may have a tensile strength of at least about 35 N and in some embodiments at least about 50 N. In still other embodiments, the fabric material will have a tensile strength of at least about 70 N.
  • the fabric materials used may exhibit one or more of the properties described in Table 1 below.
  • the fabric material may include any combination of characteristics from the “broader range” and the “narrower range,” and further, the fabric material may include in some instances characteristics that are outside the “broader range” and the “narrower range.”
  • leaflets and/or cuffs formed of UHMWPE fabric may have one or more of: a thickness of about 250 pm or less, a tensile strength of at least about 75N and preferably at least about 90N; a stiffness/flexural rigidity of about 3.0 +/- 1.75 cm; a permeability of about 850-950 mL/cm2/min; a suture retention meeting IS07198; a stretch / strain of about 20-25%; and a tear strength per meeting or exceeding ASTM D2261-13.
  • the overall properties can be similar.
  • permeability characteristic described above may apply particularly to fabrics that are coated with another material, or uncoated fabrics that have had exposure to blood for a time where the interaction of the blood with the fabric reduces the permeability of the uncoated fabric over time.
  • FIG. 1A is a perspective view of a frame of a surgical prosthetic heart valve
  • FIG. IB is a perspective view of a sewing cuff insert of a surgical prosthetic heart valve
  • FIG. 1C is a perspective view of the frame and sewing cuff insert of FIGS. 1A-B in an assembled condition and covered by a fabric;
  • FIG. 2 is a side view of a stent-supported prosthetic heart valve according to the prior art in an expanded condition;
  • FIG. 3 is a highly schematic transverse cross-section of the prosthetic heart valve taken along line 3-3 of FIG. 2 and implanted in a native valve annulus;
  • FIG. 4 is a highly schematic developed view of an expanded stent which is illustrated flattened as if it were cut longitudinally, illustrating inner and outer cuffs attached to the stent;
  • FIG. 5 is an enlarged schematic view of the fibers of a porous uncoated fabric
  • FIG. 6 is an enlarged schematic view of the fibers of a porous uncoated fabric, in which the fibers are conjugated with another material;
  • FIG. 7 is an enlarged schematic view of the fibers of a porous uncoated fabric, in which the fibers are coated with another material;
  • FIG. 8 is an enlarged view of a plain weave pattern
  • FIG. 9 is a plan view of a plain weave pattern
  • FIG. 10 is a plan view of a warp rib weave pattern
  • FIG. 11 is a plan view of a weft rib weave pattern
  • FIG. 12 is a plan view of a basket weave pattern
  • FIG. 13 is a plan view of a herringbone weave pattern
  • FIG. 14 is a plan view of a satin weave pattern
  • FIG. 15 is a plan view of a leno weave pattern
  • FIG. 16 is a plan view of a twill weave pattern
  • FIG. 17 is a plan view of a waffle weave pattern
  • FIG. 18 is a perspective view of a pile weave pattern
  • FIG. 19 is a plan view of single knit and purl knit patterns
  • FIG. 20 is an exploded view of a coated fabric including a single fabric layer sandwiched between two polymer films or layers adhered to each side of the fabric layer;
  • FIG. 21 is a perspective view of a fabric having a polymer film or layer on the edges of the top surface of the fabric layer;
  • FIG. 22 is a perspective view of a fabric having a structured upper surface and a different number of polymer layers on each side of the fabric layer;
  • FIG. 23A is a plan view of a leaflet coated on the edges of the fabric layer
  • FIG. 23B is a plan view of the underside of the leaflet coated along the sewing edge
  • FIG. 23C is a plan view of the top side of the leaflet coated along the free edge
  • FIG. 24 is a perspective view of a coated fabric having multiple layers of fabric and at least one polymer layer between each fabric layer;
  • FIG. 25 is a plan view of a heart valve leaflet fabricated from UHMWPE fibers;
  • FIG. 26 is an enlarged view of a portion of the heart valve leaflet of FIG. 25;
  • FIG. 27A is a longitudinal cross-section of a medical closure device according to an embodiment of the disclosure.
  • FIG. 27B is a highly schematic view of the medical closure device of FIG. 27 A implanted into a left atrial appendage.
  • FIG. 28 is a schematic perspective view of a leaflet formed from an uncoated fabric according to the present disclosure.
  • FIG. 29 is a schematic perspective view of a leaflet formed from a coated fabric according to the present disclosure.
  • FIG. 30 is a schematic perspective view of a leaflet formed from another coated fabric according to the present disclosure.
  • FIG. 31 is a schematic perspective view of a leaflet formed from another coated fabric according to the present disclosure.
  • FIG. 32 is a schematic perspective view of a leaflet formed from another coated fabric according to the present disclosure.
  • FIG. 33 is a schematic perspective view of a leaflet formed from another coated fabric according to the present disclosure.
  • FIG. 34 is a schematic perspective view of a leaflet formed from a partially coated fabric according to the present disclosure.
  • FIG. 34A is a schematic partial cross-section of a stent and a valve assembly incorporating the leaflet of FIG. 34;
  • FIG. 35 is a schematic perspective view of a leaflet formed from another partially coated fabric according to the present disclosure.
  • FIG. 35A is a schematic partial cross-section of a stent and a valve assembly incorporating the leaflet of FIG. 35;
  • FIG. 36 is a schematic perspective view of a leaflet formed from another partially coated fabric according to the present disclosure.
  • FIG. 37 is a schematic perspective view of a leaflet formed from another partially coated fabric according to the present disclosure.
  • FIG. 38 is a schematic perspective view of a leaflet formed from another partially coated fabric forming ribs according to the present disclosure.
  • FIG. 39 is a schematic perspective view of a leaflet formed from another partially coated fabric forming ribs according to the present disclosure.
  • FIG. 40 is a schematic perspective view of a leaflet formed from another partially coated fabric forming spots according to the present disclosure;
  • FIG. 41 is a schematic perspective view of a leaflet formed from another coated fabric according to the present disclosure.
  • FIG. 41 A is a cross-sectional view of a variant of the leaflet of FIG. 41 ;
  • FIG. 41B is a cross-sectional view of a further variant of the leaflet of FIG. 41 ;
  • FIG. 42 is a schematic perspective view of a leaflet formed from another partially coated fabric according to the present disclosure.
  • FIG. 43 is a schematic perspective view of a leaflet formed from another coated fabric incorporating indicia according to the present disclosure.
  • FIG. 43A is a highly schematic transverse cross-section of a prosthetic heart valve incorporating a plurality of the leaflets of FIG. 43;
  • FIG. 44 is a schematic perspective view of a leaflet formed from another uncoated fabric incorporating indicia according to the present disclosure
  • FIGS. 44A-44C are highly schematic transverse cross-sections of a prosthetic heart valve incorporating a plurality of the leaflets of FIG. 44 with different indicia;
  • FIG. 45 is a schematic perspective view of a leaflet formed from another partially coated fabric incorporating holes according to the present disclosure.
  • FIG. 45A is a schematic partial cross-section of a stent and a valve assembly including a cuff and the leaflet of FIG. 45;
  • FIG. 45B is a schematic partial cross-section of a stent and a valve assembly incorporating the leaflet of FIG. 45;
  • FIG. 46 is a schematic perspective view of a stent having a cuff formed from a coated fabric incorporating radiographic bands according to the present disclosure
  • FIG. 46 A is a schematic partial cross-section of the stent and cuff of FIG. 46;
  • FIG. 47 is a schematic perspective view of a leaflet formed from a fabric according to the present disclosure including a single stitch in a major surface of a leaflet;
  • FIG. 48 is a schematic perspective view of a leaflet formed from a fabric according to the present disclosure including a single stitch in the free edge of a leaflet;
  • FIG. 49 is a schematic perspective view of a leaflet formed from a fabric according to the present disclosure including multiple stitches on a major surface of a leaflet;
  • FIG. 50 is a schematic perspective view of a leaflet formed from a fabric according to the present disclosure including a fabric layer and coating layer having multiple stitches in the free edge of a leaflet;
  • FIG. 51 is a schematic perspective view of a leaflet formed from a fabric according to the present disclosure including a fabric layer and coating layer having a single suture line extending across a major surface of a leaflet from the attachment edge to the free edge;
  • FIG. 52 is a schematic perspective view of a leaflet formed from a fabric according to the present disclosure including a plurality of suture lines extending across a major surface of a leaflet from the attachment edge to the free edge;
  • FIG. 53 is a schematic perspective view of a leaflet formed from a fabric according to the present disclosure including a fabric layer and coating layer having a discontinuous suture line extending across a major surface of a leaflet from the attachment edge to the free edge;
  • FIG. 54 is a schematic perspective view of a leaflet formed from a fabric according to the present disclosure including a fabric layer and coating layer having a single suture line extending along the free edge of a leaflet;
  • FIG. 55 is a schematic perspective view of a leaflet formed from a fabric according to the present disclosure including a discontinuous suture line extending along the free edge of a leaflet;
  • FIG. 56 is a schematic perspective view of a leaflet formed from a fabric according to the present disclosure including a fabric layer and coating layer having a single suture line extending along the attachment edge of a leaflet;
  • FIG. 57 is a schematic perspective view of a leaflet formed from a fabric according to the present disclosure including a fabric layer and coating layer having a discontinuous suture line extending along the attachment edge of a leaflet;
  • FIG. 58 is a schematic perspective view of a leaflet formed from a fabric according to the present disclosure including a single suture line extending along the free edge of a leaflet through a partial coating layer;
  • FIG. 59 is a schematic perspective view of a leaflet formed from a fabric according to the present disclosure including a single suture line extending along the free edge of a leaflet disposed underneath a partial coating layer;
  • FIG. 60 is a schematic perspective view of a leaflet formed from a fabric according to the present disclosure including an area of increased weave density extending along and adjacent the free edge of a leaflet;
  • FIG. 61 is a schematic perspective view of a leaflet formed from a fabric according to the present disclosure including an area of increased weave density extending along the attachment edge of a leaflet;
  • FIG. 62 is a schematic view of a leaflet formed from a fabric according to the present disclosure including a pleat formed therein;
  • FIG. 63 is a schematic perspective view of a leaflet formed from a fabric according to the present disclosure including a fabric layer and coating layer having a single wire extending from the attachment edge to the free edge of a leaflet;
  • FIG. 64 is a schematic perspective view of a leaflet formed from a fabric according to the present disclosure including a fabric layer and coating layer having a discontinuous wire extending from the attachment edge to the free edge of a leaflet;
  • FIG. 65 is a schematic perspective view of a leaflet formed from a fabric according to the present disclosure including a fabric layer and coating layer having a single wire extending across and generally along the free edge of the leaflet, the single wire being disposed between the fabric layer and a partial coating layer;
  • FIG. 66 is a schematic perspective view of a leaflet formed from a fabric according to the present disclosure including a single wire extending across a major surface of the leaflet and generally along the attachment edge of a leaflet;
  • FIG. 67A is a schematic perspective view of a leaflet formed from a fabric according to the present disclosure including a single wire extending across a major surface of the leaflet and adhered thereto generally along a line which parallels the leaflet’s free edge; and
  • FIG. 67B is a schematic perspective view of a leaflet formed from a fabric according to the present disclosure including a plurality of concentric semicircular wires roughly paralleling the attachment edge.
  • the term “inflow end” refers to the end of the heart valve through which blood enters when the valve is functioning as intended
  • the term “outflow end” refers to the end of the heart valve through which blood exits when the valve is functioning as intended.
  • proximal and upstream refer to the inflow end of a prosthetic heart valve and these terms may be used interchangeably.
  • distal refers to the outflow end of a prosthetic heart valve and also may be used interchangeably.
  • the terms “generally,” “substantially,” and “about” are intended to mean that slight deviations from absolute are included within the scope of the term so modified.
  • the lengthwise or axial direction refers to a direction parallel to a longitudinal axis passing through the center of the stent or heart valve from the inflow end to the outflow end.
  • the circumferential direction refers to a direction extending along the circumference of the prosthetic heart valve.
  • FIGS. 1A-1C illustrate a surgical heart valve 10 and several components thereof.
  • Surgical heart valve 10 may be surgically implanted into a patient to replace a native heart that may be not functioning as intended, such as the aortic valve, mitral valve, pulmonary valve, or the tricuspid valve.
  • Surgical heart valve 10 may have a non-collapsible frame 12, shown in FIG. 1 A, having a generally annular shape.
  • Frame 12 may be formed of any suitable biologically compatible material, including titanium, Elgiloy ® MP3N, or another metal, which may be laser cut from a tube, or from a biologically compatible polymer, such as PEEK or acetal.
  • frame 12 Since the valve of the illustrative embodiment is a tricuspid valve (e.g., for use in replacing a patient’s aortic valve), frame 12 has three commissure posts 12a, 12b, and 12c that are equally spaced from one another around the circumference of the frame. Each commissure post stands up from the annularly continuous base 16 of frame 12, and they support and/or serve as attachment points for a plurality of prosthetic leaflets (not shown). Although frame 12 is illustrated with three commissure posts 12a-c for supporting a three-leaflet valve assembly, it should be understood that the frame could include more or fewer commissure posts for supporting a corresponding number of prosthetic leaflets.
  • Base 16 of frame 12 may include a blood-inflow edge 18 that is scalloped as one proceeds around the frame to approximately match the natural scallop of the native valve annulus.
  • the frame may also include an annularly continuous blood-outflow edge 20, which merges with and becomes part of each commissure post 12a-c.
  • the inflow edge 18, outflow edge 20, and flexibility of the frame are designed to help ensure proper opening and coaptation of the leaflets of the prosthetic heart valve during use.
  • the prosthetic leaflets may be formed of a biological material, such as bovine pericardium, or from any of the engineered leaflet materials disclosed herein.
  • Frame 12 may be covered by a fabric covering (not shown), particularly over each commissure post 12a-c.
  • a fabric covering is reemay fabric, which is a spun form of polyester.
  • a ring 22 (FIG. IB), which may be formed of silicone, may be positioned around the outside of the inflow edge 18 of frame 12. The entire frame 12 and ring 22 may be completely covered inside and out by a further fabric layer. Subsequently, a layer of tissue 24 may be applied over the fabric layer, including both inside and outside of frame 12 and over ring 22.
  • Tissue layer 24 is typically formed of any mammalian tissue, and in particular any mammalian pericardium tissue, such as porcine, equine, or bovine pericardium.
  • the covered ring 22 serves as a sewing cuff for sewing the prosthetic heart valve into the native valve annulus of the patient.
  • the collapsible/expandable prosthetic heart valves of the disclosure have an expanded condition and may also have a collapsed condition.
  • aspects of the disclosure apply to a collapsible/expandable prosthetic heart valve for replacing a native aortic valve, the disclosure is not so limited, and may apply to prosthetic valves for replacing other types of cardiac valves, including, the mitral valve, the tricuspid valve and the pulmonary valve.
  • the disclosure limited to a specific method of delivery.
  • the collapsible/expandable prosthetic heart valves described herein may be delivered via any suitable transcatheter delivery route, including a transfemoral route, a transvenous route, a transapical route, a transjugular route, a transaortic route, a transsubclavian route, etc. Further, the collapsible/expandable prosthetic heart valves described herein may be delivered via traditional surgical routes, or any suitable minimally invasive route.
  • FIG. 2 shows one embodiment of a collapsible/expandable stent-supported prosthetic heart valve 100 according to the prior art, the prosthetic heart valve being shown in an expanded condition.
  • Prosthetic heart valve 100 is designed to replace the function of the native aortic valve of a patient, and includes a stent 102 which serves as a frame for the valve elements.
  • Stent 102 extends along a lengthwise or longitudinal axis L from an inflow or annulus end 130 to an outflow or aortic end 132, and includes an annulus section 140 adjacent inflow end 130 and an aortic section 142 adjacent outflow end 132.
  • Annulus section 140 may be in the form of a cylinder having a substantially constant diameter along its length, and may have a relatively small transverse cross-section in the expanded condition in comparison to the transverse cross-section of aortic section 142.
  • a transition section 141 may taper outwardly from annulus section 140 to aortic section 142.
  • Each of the sections of stent 102 includes a plurality of cells 112 formed by interconnected struts 114.
  • Each cell 112 may include four struts 114 connected together generally in a diamond shape so as to form a cell that may be readily collapsed and expanded. It will be appreciated that a smaller or larger number of struts may be used to form cells having a different shape.
  • the cells 112 in each section of stent 102 may be connected to one another in one or more annular rows around the stent.
  • annulus section 140 may have two annular rows of complete cells 112, with the cells in one annular row offset by one-half cell width in the circumferential direction from the cells in the other annular row.
  • Aortic section 142 and transition section 141 may each have one or more annular rows of complete or partial cells 112.
  • the cells in aortic section 142 may be larger than the cells in annulus section 140 so as to better enable prosthetic valve 100 to be positioned within the aortic annulus without the structure of stent 102 interfering with blood flow to the coronary arteries.
  • stent 102 elongates in the direction of longitudinal axis L as the cells collapse when the stent transitions from the expanded condition to the collapsed condition, and shortens in the direction of longitudinal axis L as the stent transitions from the collapsed condition to the expanded condition.
  • Stent 102 may include one or more retaining elements 118 at outflow end 132, the retaining elements being sized and shaped to cooperate with retaining structures provided on a delivery device (not shown).
  • the engagement of retaining elements 118 with the retaining structures on the deployment device may help maintain prosthetic heart valve 100 in assembled relationship with the deployment device, minimize longitudinal movement of the prosthetic heart valve relative to the deployment device during unsheathing or resheathing procedures, and help prevent rotation of the prosthetic heart valve relative to the deployment device as the deployment device is advanced to the target location and during deployment.
  • One such deployment device is described in U.S. Patent Publication No. 2012/0078352, the disclosure of which is hereby incorporated by reference herein.
  • Stent 102 may also include a plurality of commissure attachment features 116 for mounting the leaflet commissures of the valve assembly to the stent.
  • each commissure attachment feature 116 may lie at the intersection of four cells 112, two of the cells being adjacent one another in the same annular row, and the other two cells being in different annular rows and lying in end-to-end relationship.
  • Commissure attachment features 116 may be positioned entirely within annulus section 140 or at the juncture of annulus section 140 and transition section 141, and may include one or more eyelets or apertures which facilitate the suturing of the leaflet commissures to stent 102.
  • Stent 102 may be formed as a unitary structure, for example, by laser cutting or etching a tube of a superelastic and/or shape-memory metal alloy, such as a nickel-titanium alloy of the type sold under the designation nitinol. It should be understood that stent 102 may include other forms of commissure attachment features, or may omit commissure attachment features, with the prosthetic leaflets being attached to the stent via other mechanisms, such as direct suturing or via intermediary attachment panels. Examples of other attachment modalities may be found in U.S. Patent Application No. 16/568,345, filed September 12, 2019, the disclosure of which is hereby incorporated by reference herein.
  • Prosthetic heart valve 100 includes a valve assembly 104 which, in one embodiment, may be positioned entirely in the annulus section 140 of stent 102.
  • Valve assembly 104 includes a plurality of leaflets 108 that collectively function as a one-way valve by coapting with one another, and a cuff 106 positioned on the luminal surface of stent 102 surrounding leaflets 108.
  • cuff 106 is shown in FIG. 2 as being disposed on the luminal or inner surface of annulus section 140, the cuff may be disposed on the abluminal or outer surface of the annulus section, or may cover all or part of either or both of the luminal and abluminal surfaces of the annulus section.
  • prosthetic heart valve 100 is intended to replace the aortic valve (which ordinarily is a tri-leaflet valve), it is shown in FIG. 2 with three leaflets 108. Adjacent leaflets 108 join one another at leaflet commissures. Each of the leaflet commissures may be sutured to a respective one of the three commissure attachment features 116. Between the leaflet commissures, each leaflet 108 may be sutured to stent 102 and/or to cuff 106 along an attachment edge 120, indicated with broken lines in FIG. 2. Leaflets 108 may be joined to stent 102 and/or to cuff 106 by techniques known in the art other than suturing.
  • leaflets 108 are free to move radially inward to coapt with one another along their free edges.
  • leaflets 108 When the pressure in the aorta is greater than the pressure in the left ventricle, leaflets 108 are forced closed and coapt with one another along their free edges, blocking blood from flowing through prosthetic heart valve 100 in a retrograde direction from outflow end 132 to inflow end 130 which allows the left and right coronary arteries to fill and feed blood to the heart muscle. It will be appreciated that prosthetic heart valves according to aspects of the present disclosure may have more or less than the three leaflets 108 and commissure attachment features 116 shown in FIG. 2 and described above.
  • Cuff 106 may be scalloped at the inflow end 130 of stent 102, and may have a zig-zag structure at its outflow end, following certain stent struts 114 up to commissure attachment features 116 and other stent struts closer to the inflow end of the stent at circumferential positions between the commissure attachment features.
  • leaflets 108 When open, leaflets 108 may remain substantially completely within annulus section 140, or they may be designed to extend into transition section 141.
  • substantially the entirety of valve assembly 104 is positioned between the inflow end 130 of stent 102 and commissure attachment features 116, and none of the valve assembly is positioned between the commissure attachment features and the outflow end 132 of the stent.
  • prosthetic heart valve 100 may be used to replace a native heart valve, such as the aortic valve, a surgical heart valve, or a heart valve that has undergone a surgical procedure.
  • Prosthetic heart valve 100 may be delivered to the desired site (e.g., near the native aortic annulus) using any suitable delivery device.
  • prosthetic heart valve 100 is disposed inside the delivery device in the collapsed condition.
  • the delivery device may be introduced into the patient using any known percutaneous procedure, such as a transfemoral, transapical, transvenous, or transseptal delivery procedure. Once the delivery device has reached the target site, the user may deploy prosthetic heart valve 100.
  • prosthetic heart valve 100 Upon deployment, prosthetic heart valve 100 expands into secure engagement within the native aortic annulus. When prosthetic heart valve 100 is properly positioned inside the heart, it works as a one-way valve, allowing blood to flow in one direction and preventing blood from flowing in the opposite direction. (See U.S. Patent No. 7,585,321 FIGS. 13a-16b and accompanying disclosure; U.S. Patent No. 6,458,153 FIGS. 20A-20I and accompanying disclosure.)
  • FIG. 3 is a highly schematic transverse cross-section of prosthetic heart valve 100 taken along line 3-3 of FIG. 2 and showing leaflets 108 disposed within native valve annulus 250.
  • the substantially circular annulus section 140 of stent 102 is disposed within a non-circular native valve annulus 250.
  • gaps 200 are formed between the heart valve and native valve annulus 250. Retrograde blood flow through these gaps and around the outside of the valve assembly 104 of prosthetic heart valve 100 can result in PV leak or regurgitation and other inefficiencies which can reduce cardiac performance.
  • FIG. 4 depicts a collapsible/expandable prosthetic heart valve very similar to that shown in FIGS. 2 and 3, except that it is shown as if cut longitudinally and flattened.
  • the heart valve can include a stent 302 with commissure attachment features 316.
  • a cuff 306 similar or identical to cuff 106 may be positioned on the luminal and/or abluminal surface of stent 302. Indeed, cuff 306 in FIG. 4 is illustrated as being positioned on the luminal or inner surface of stent 302.
  • outer cuff 350 may have a substantially rectangular shape and may be wrapped around the circumference of stent 302 at the inflow end of the stent so as to overlap in the longitudinal direction of the stent with cuff 306. This is only one embodiment of such an exterior or outer cuff.
  • Outer cuff 350 may be formed as a single piece of material having a proximal edge 352, two side edges 354, 356, and a distal edge 358.
  • the proximal edge 352 of outer cuff 350 is coupled to stent 302 and/or to inner cuff 306 at or near the inflow end of the stent, for example by a continuous line of sutures (not shown), with the side edges 354 and 356 of the outer cuff joined to one another, so that retrograde blood flow (flowing from the outflow end toward the inflow end) entering the space between the outer cuff and the inner cuff cannot pass in the retrograde direction beyond the combined cuffs.
  • the distal edge 358 of the outer cuff may be attached to stent 302 and/or to inner cuff 306 at locations that are spaced apart in the circumferential direction.
  • the distal edge 358 of outer cuff 350 may, for example, be sutured to stent 302 at attachment points SI located where each cell 312 in the proximal-most row of cells intersects with an adjacent cell in that same row.
  • outer cuff 350 may tend to billow outwardly, helping to fill any of gaps 200 between the prosthetic heart valve and native valve annulus 250.
  • Inner cuff 306 may be located either on the luminal or abluminal side of stent 302, or on both sides.
  • Outer cuff 350 may also comprise multiple pieces of material that, when joined together, form a shape and provide a function that are similar to what has been described above. Also, rather than being formed of a single substantially rectangular piece of material that is wrapped around the circumference of stent 302, outer cuff 350 may be formed as a continuous annular web without side edges 354, 356. Preferably, outer cuff 350 has an axial height measured from its proximal edge 352 to its distal edge 358 that is approximately half the axial height of a cell 312 in the proximal-most row of cells in stent 302 as measured along the major axis of the cell between two of its apices when the cell is in an expanded condition.
  • outer cuff 350 may have other suitable heights, such as the full axial height of a cell 312 in the proximal-most row of cells, or more or less than the full axial height of a cell 312 in the proximal-most row of cells. Still further, although inner cuff 306 and outer cuff 350 are described above as separate pieces of material joined to stent 302 and to each other, the cuffs may be formed integrally with one another from a single piece of material that is wrapped around the inflow edge of the stent, with the distal edge 358 of the outer portion of the cuff joined to the stent and/or to the inner portion of the cuff at attachment points SI as described above.
  • proximal edge 352 of outer cuff 350 does not need to be sutured to stent 302, although it still may be preferable to provide such attachment.
  • the various valve components including, without limitation, inner cuffs, outer cuffs and leaflets, and valve assemblies made therefrom, may be attached to each other and/or to the stent in any conventional manner, including suturing, gluing, molding, welding, heating, cross-linking, and the like. ( See U.S. Patent Nos. 6,821,297; 6,458,153; 7,585,321; 5,957,949.)
  • Valve assemblies such as valve assembly 104 comprising inner cuff 106/306, leaflets 108, as well as outer cuff 350, may be formed of the same or different materials, including any suitable biological material, including “fixed” bovine or porcine tissue, or a polymer such as, for example, polyolefins such as polytetrafluoroethylene (PTFE), polyethylenes including ultra-high molecular weight polyethylene (UHMWPE), and polypropylene, as well as polyurethane, PEEK, polyvinyl alcohol, silicone, or combinations thereof.
  • PTFE polytetrafluoroethylene
  • UHMWPE ultra-high molecular weight polyethylene
  • polypropylene as well as polyurethane, PEEK, polyvinyl alcohol, silicone, or combinations thereof.
  • At least one of the components of a valve including, without limitation, leaflets or cuffs, valve assemblies, and the like, is produced from an uncoated or coated fabric as described herein.
  • coated and uncoated fabric materials described herein may be used in surgical heart valves that are similar to surgical heart valve 10 or surgical heart valves that are very different therefrom.
  • the presently disclosed coated and uncoated fabric materials may be used in collapsible/expandable prosthetic heart valves that are similar to prosthetic heart valve 100, or prosthetic heart valves that are very different therefrom, such as heart valves having a balloon-expandable stent; heart valves that do not have an aortic section; heart valves in which the stent has an hourglass profile, right cylindrical sections or ovoid cross-sections; heart valves intended to replace other cardiac valves, such as the mitral valve; etc.
  • the stent may be made of a single or multiple bent wires such as illustrated in U.S. Patent No. 5,411,552 or U.S. Patent No. 5,855,601, forming a zigzag or sinusoidal shape, or may be made from interwoven or intercrossing bars such as shown in U.S. Patent No. 5,545,214 and U.S. Patent No. 7,585,321.
  • the stent may also be formed of woven materials which can be such as shown in EP 2,926,766, which is hereby incorporated by reference herein for its teaching of a woven stent and for its teachings regarding the mounting of a cuff and/or sac on the interior or exterior of a stent.
  • the stent is made from a laser-cut nitinol tube.
  • a balloon-expandable stent may be composed of biocompatible metals known in the art, including but not limited to, cobalt chromium and stainless steel.
  • the stent may be continuous or discontinuous (made in sections that are attached to one another directly or indirectly- see, for example, U.S. Patent No. 5,957,949). Therefore, the descriptions herein of surgical heart valve 10 and collapsible/expandable prosthetic heart valve 100 should in no way be considered as limiting the features and applications of the coated and uncoated fabric materials disclosed herein.
  • one or more of the valve components and, in particular, the inner and/or outer cuff(s) and/or one or more leaflets may be made from a woven or knitted fabric, or from a felt or other polymeric fabric that is nonwoven.
  • fabric refers to a polymer-fiber containing material having filaments, threads, yarns, or other strands (collectively, “fibers”) that are interlaced with one another to form a web.
  • the fibers may be formed of any one or more of a variety of materials, including natural materials, polymers, or blends of natural materials and polymers, so long as it includes a majority of polymer fibers.
  • the natural materials may include cotton, wool, hemp, jute, silk, linen, alpaca, cashmere and the like.
  • the polymer fibers may include, for example, polyolefins such as polytetrafluoroethylene (PTFE) (including expanded, stretched, low molecular weight, medium molecular weight, high molecular weight and ultra-high molecular weight (UHMW)), polyethylenes (including low, medium, high and ultra-high molecular weight polyethylene (UHMWPE -e.g., having an average molecular weight of between about 2 and about 7.5 million atomic mass units)), and polypropylene (including low, medium, high and ultra-high molecular weight polypropylene (UHMWPP)), as well as polyurethane, PEEK, polyvinyl alcohol, silicone, rayon, polyesters, aramid, spandex, or combinations thereof.
  • PTFE polytetrafluoroethylene
  • UHMWPE ultra-high molecular weight polyethylene
  • the fibers may have any cross-sectional shape, including round, rectangular, triangular, polygonal, oval, etc. Moreover, the fibers may be selected to have desired dimensions, such as diameter, width, thickness and/or length. The fibers may also be porous or nonporous, and drug-eluting or non drug-eluting. In addition, the fibers may each consist of a single strand or filament, or of multiple strands or filaments. For fibers comprised of multiple strands or filaments, the strands or filaments may be braided, twisted or otherwise joined together in a bundle.
  • fibers shall include both individual fibers as well as fiber bundles.
  • the fibers may be selected based on certain properties, such as creep, tensile strength, elastic modulus, strain/elongation, compressibility, flexural rigidity and stiffness, and twist direction and magnitude. Other properties that may influence the selection of certain fibers include melt flow viscosity, percent spin finish, linear density, tenacity, melting temperature, biocompatibility, purity, Denier, color, radiopacity, surface friction and entanglement.
  • the individual fibers may be uncoated, or they may be coated with another material.
  • the fiber may be conjugated (i.e., chemically reacted) with another material, for example, a therapeutic drug or a lubricious material.
  • the fiber may be coated with a polymer or other material.
  • a porous fiber may be infused with a polymer, a therapeutic drug, a lubricity-promoting agent or another material. Any known technique may be used to coat the fiber with a polymer or other material, including spray coating, dip coating and the like.
  • the fibers may be allowed to dry or, for polymer coatings, the polymer may be solidified by cross-linking. It will be appreciated that, for coated fibers, the coating may be applied uniformly around the surface of the fiber, or it may be applied to only portions of the fiber surface and/or along only portions of the fiber length.
  • Uncoated fabrics include fabrics formed of woven or knitted fibers and fiber bundles, as well as felts, mats and other nonwoven materials formed from interlaced fibers.
  • the fabrics of the present disclosure may be formed from fibers having any of the compositions or any of the properties described above.
  • “fabrics” must include at least a majority of polymer fibers.
  • the properties of the resulting fabric will depend, of course, on the properties of the fibers from which the fabric is formed, as well as on the manner in which the fabric is formed.
  • the fabric may be created by knitting or weaving together fibers of one or more materials through various weaving or knitting techniques.
  • the fabrics may be formed by randomly interlacing the fibers to form a felt or matted web. By controlling the forming process, certain desired properties in the resultant fabric may be obtained.
  • controlling the fabric “thread count,” or number of fibers (or fiber bundles) per square inch, or for knitted fabrics, controlling the fabric “stitch density,” or number of needle loops per square inch, can affect at least the overall strength of the fabric, as well as the fabric’s flexibility and porosity.
  • the weave of the fabric may also determine the extent of porosity in the fabric.
  • the fabric’ s porosity corresponds to the number and size of the open areas formed between the fibers as a result of the weaving or knitting process.
  • the fabric when used as a component of a prosthetic heart valve, the fabric, when the prosthetic heart valve has been implanted, may be in contact with tissue and may promote a healing response.
  • the porosity of the woven or knitted fabric may allow cells to flow through the valve component, but after blood makes contact with the fabric, the fabric may become less permeable or impermeable.
  • an uncoated fabric may promote cell adhesion, wherein cells may attach to a single fiber of the fabric or to a plurality of fibers of the fabric.
  • the cells may adhere or attach to the fabric without inhibiting the expected performance of the material.
  • the cells may attach to a single fiber of the fabric.
  • Cell adhesion may be aided by the deposition of blood proteins, plasma, coagulation products, fibrin or other materials.
  • cells may migrate into the prosthetic heart valve from the adjacent tissue and may attach or adhere to the fabric components.
  • cells from the blood may be entrapped in the fabric and may attach or adhere to individual fibers of the fabric.
  • the adhesion of cells to the fabric may also be influenced by the composition of the fibers and whether the fibers themselves are coated or uncoated, and if coated, the composition of the coating.
  • porous fibers may be impregnated with a drug or other material that may either promote or retard cell adhesion.
  • the individual fibers may be either partially or fully conjugated or coated with a polymer, a therapeutic drug and/or another material prior to forming the fibers into a fabric.
  • FIGS. 5-7 show different embodiments of an uncoated fabric. In one embodiment, shown in FIG. 5, the individual fibers 390 of the fabric are uncoated. In another embodiment, shown in FIG.
  • the individual fibers 390 of the fabric may be conjugated with another material, for example, a therapeutic drug, before the fibers are woven or knitted to form the uncoated fabric.
  • the individual fibers 390 of the fabric may be coated with a polymer or other material before the fibers are woven or knitted to form the uncoated fabric.
  • every fiber of the fabric may be so conjugated or coated, either partially or fully, or only some of the fibers of the fabric may be so conjugated or coated.
  • the fabrics may also be engineered to have certain mechanical properties, such as a desired creep, compression, burst strength, suture retention, flexural rigidity/stiffness, tearing strength, delamination strength, and stretch/elongation.
  • Other fabric properties that may be sought include a specific anisotropy, color, weight, extractable content, permeability, radiation sensitivity, radiopacity, moisture sensitivity, temperature sensitivity, and/or chemical sensitivity. As noted, many of these parameters may be influenced by the particular fibers used to form the fabric, while others may be more influenced by the manner in which the fabric is formed from the fibers.
  • the fabric may include one or more radiopaque fibers to assist in identifying the location and orientation of one or more features of the prosthetic heart valve or other medical device in which the fabric is incorporated.
  • the fabrics may be engineered to have a desired thread count, a desired tensile strength, a desired areal density, and/or a desired thickness, all measured before the medical device incorporating the fabric is implanted in a patient.
  • the fabric is a woven fabric, it preferably has a thread count of at least about 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000 or more total fibers per square inch per layer of fabric.
  • the thread count need not be symmetrical.
  • the thread count is from about 200 to about 500 by about 200 to about 500 fibers in a square inch (200-500 x 200-500), and in another embodiment is from about 300 to about 500 by about 100 to about 300 fibers in a square inch (300-500 x 100-300).
  • the fabric is a high density weave having more than 300 fibers per square inch. Further, the thread count in one portion of the fabric may be different from the thread count in another portion of the fabric.
  • the thread count at the attachment edge may be greater than the thread count in the belly portion or at the free edge of the leaflet.
  • the greater thread count at the attachment edge produces a fabric with greater strength in the region at which the leaflet is attached to the cuff and/or stent and experiences a large amount of stress in use.
  • the density of the weave may be adjusted, and often reduced, to promote flexibility and adhesion of layers, including adhesion through the fabric of a coating on one major surface of the fabric to a coating on the other major surface of the fabric.
  • the fabric is a knitted fabric, it typically has a lower thread count or stitch density than a woven fabric. Knitted fabrics may have a stitch density of from about 2 to about 750 per square inch or from about 5 to about 500 per square inch.
  • the fabric has a tensile strength of at least about 50N, and in other embodiments about 60N. In still other embodiments, the tensile strength is about 70N or more. A tensile strength of at least about 75N may be used, as may a tensile strength of at least about 85N or at least about 100N.
  • woven or knitted fabric has an areal density of at least about 0.5 ⁇
  • weave density and thread counts balance the need for strength, flexibility and porosity.
  • pore density between woven/knitted fabric fibers should not be large enough to cause appreciable leakage through the fabric.
  • the fewer the number of fibers and/or the larger the number of pores in the fabric the greater will be the flexibility of the fabric and the more a synthetic fabric leaflet will resemble a healthy native leaflet.
  • the woven or knitted fabric in one embodiment has an areal density of at most about 1.3 0.1 ounces/yard 2 , and in another embodiment, an areal density of no more than about 1.0 0.1 ounces/yard 2 .
  • the uncoated fabric has a thickness of about 10 mpi to about 200 mpi, and in other embodiments, a thickness of about 20 mpi to about 100 mpi. In some embodiments, the thickness of the fabric is from about 50 mpi to about 100 mpi. Thickness is a balance between durability, resilience, and flexibility.
  • the fabric leaflets of the disclosure are often only about 20% of the thickness of most tissue leaflets used in conventional collapsible heart valves, which are about 300-450 mpi thick, or about 10% of the thickness of most tissue leaflets used in surgical heart valves, which are about 400-800 mpi thick.
  • any of the properties of the fabric may be selected depending on the particular application for the fabric. For example, while some parameters may be suitable for fabrics forming the cuffs and/or leaflets of a collapsible/expandable prosthetic heart valve, fabrics having other parameters may be better suited for other medical devices described below.
  • FIGS. 8 to 19 illustrate various techniques that may be used to form the fabric.
  • the fabric may be formed by interlacing two or more fibers, or in the case of knit fabrics at least one fiber, which can be accomplished in several ways. Some of the methods for interlacing two or more fibers include weaving, knitting, braiding, plaiting, electro spinning, 3-D printing or entangling the fibers through felting, bonding or lamination. Woven fabrics may be fabricated through various techniques. As used herein in connection with the various weaving techniques, “filling” or “weft” refers to fibers that extend along the width of the fabric, while “warp” refers to fibers that extend along the length of the fabric. A plain weave, shown in FIGS.
  • the warp rib weave produces a rib or cord in the weft direction, while the weft rib weave produces a rib or cord effect in the warp direction.
  • a weft weave of polyethylene terephthalate (PET) may be particularly desirable for certain applications, such as for cuffs and/or leaflets of prosthetic valves.
  • PET polyethylene terephthalate
  • Another derivative of the plain weave is a basket weave, in which both the filling fiber and the warp fiber run in double or triple strands.
  • a basket weave shown in FIG. 12
  • two or more adjacent rows of the filling fiber are passed in the same pattern over and under two or more adjacent rows of the warp fiber.
  • Another weaving technique that may be used to fabricate a woven fabric is the twill weave, shown in FIG. 16.
  • the twill weave is known for producing a diagonal pattern when the filling fibers are woven over and under two or more adjacent warp fibers. ( Twill weave, 2019, https://www.dictionary.com/browse/twill-weave, accessed on Oct. 11, 2019.)
  • a version of the twill weave includes the herringbone weave, shown in FIG.
  • Additional weaving techniques can be used to form the fabric as well.
  • One additional weaving technique is the leno weave, shown in FIG. 15, a principal of interweaving in which some of the warp ends do not lie parallel to one another, but are twisted partly around other ends.
  • Another weaving technique is the Bedford cord, in which the weave produces longitudinal warp lines in the fabric with fine sunken lines in between.
  • a waffle weave as shown in FIG. 17 can also be used by weaving the fabric into a pattern resembling a honeycomb. ⁇ Honeycomb, The Free Dictionary, https://www.thefreedictionary.com/waffle-i-weave, accessed on Oct, 11, 2019.) Also usable is a pile weave, which incorporates a loop pattern into the weave to produce a fabric with a raised, dense surface.
  • FIG. 18 An example of a pile weave is shown in FIG. 18.
  • a jacquard weave is another available technique which produces a fabric on a special loom because of the complex woven-in designs.
  • a dobby weave requires a special loom attachment to incorporate small, geometric, textured, repeated woven-in designs.
  • Tapestry weaving in which the warp fibers do not show at all, is another available technique.
  • An additional weaving technique is the double cloth weave, in which the fabric is made of two or more sets of warp fibers and one or more sets of weft or filling fibers that are interconnected to form a two-layered fabric. ( Double Cloth, Mar. 20, 2019, https://en.wikipedia.Org/wiki/Double_cloth#cite_ref-text_2-0, accessed on Oct. 11, 2019.)
  • Knitting involves interlacing loops of at least one fiber.
  • the main fabrics produced by knitting are weft knits, specialized weft knits and warp knits.
  • a weft knit fabric can either be a single knit or a double knit.
  • a single knit fabric is produced by one set of needles, while a double knit fabric is produced by two sets of needles. (Random House Kernerman Webster's College Dictionary, 2010, K Dictionaries Ltd.)
  • the most common example of a single knit fabric is a single jersey.
  • the most common double knit fabrics include rib knit, purl knit, interlock knit, cable fabric, bird’s eye, cardigans, Milano ribs and pointelle.
  • the rib knit fabric is known for having a ribbed pattern.
  • Rib-knit Merriam-Webster, 2019, https://www.merriam-webster.com /dictionary/rib-knit, accessed on Oct, 11, 2019.
  • a fabric with an interlock knit is a variation of the rib knit fabric with closely interlocking stitches providing the tightest weave.
  • Fabrics produced with a specialized weft knit include intarsia, jacquard jerseys, knitted terry, knitted velour, sliver knit, fleece and French terry.
  • warp knitting commonly used, raschel and tricot.
  • Raschel knitting produces fabrics by using latch needles, while tricot knitting uses a bearded needle. (Id.)
  • polymer fabrics may be coated, either partially or completely, with one or more polymer layers, resulting in a coated fabric.
  • “Coated fabric” in accordance with the disclosure means any of the uncoated fabrics described above, to which a polymer coating, film or layer is deposited or applied, either partially or completely covering at least a portion of one surface or edge of the fabric.
  • the materials used for the fabric, as described previously, can be used for any coating or partial coating.
  • Individual coatings may be the same as or different from one another and from the fabric, and include, without limitation, a PTFE, such as ultra-high molecular weight PTFE (UHMWPTFE) and expanded or stretched PTFE, a polyethylene, such as UHMWPE, and a polypropylene, such as UHMWPP, copolymers or block copolymers of polyethylenes and polypropylenes, and combinations or blends thereof.
  • a PTFE such as ultra-high molecular weight PTFE (UHMWPTFE) and expanded or stretched PTFE
  • a polyethylene such as UHMWPE
  • polypropylene such as UHMWPP
  • copolymers or block copolymers of polyethylenes and polypropylenes and combinations or blends thereof.
  • Other polymers which may be used alone or in combination with those mentioned above include, without limitation, polyurethanes, acrylics, polyesters, polyamides, polyimides, vinyl acetates, alkyds, ep
  • a woven fabric could include fibers of one of or more of these materials or fiber bundles of one or more of these materials.
  • Individual layers of a coating could be made of a single one of these materials or of blends/copolymers of them. When more than one coating layer is used, each of the layers may have the same or a different composition.
  • the polymer coating may be produced using films that are directionally oriented in the same or in different directions.
  • a polymer film may be applied to a top side of the fabric in one direction and a second polymer film may be applied to the bottom side of the fabric in a different direction.
  • the polymer film on each side of the fabric may be applied in the same direction or in different directions such that one polymer film is oriented differently from the polymer film that it sits on top of.
  • the fabric/coating could further include or be coated with a drug or active pharmaceutical ingredient (API) or the coating could include the API, which gradually elutes from it.
  • API active pharmaceutical ingredient
  • APIs may include, for example, Sirolimus, Paclitaxel, Everolimus, or any treatment to enhance resistance to calcification. APIs may also include growth factors, such as vascular endothelial growth factor (VEGF) and transforming growth factor (TGF-beta). It may also be coated with, or the coating may include hyaluronan, hyaluronic acid, glycosaminoglycans (GAGs), Heparin, or amino acids for cell attachment sites, and anti-oxidants such as super oxide dismutase or ascorbic acid.
  • VEGF vascular endothelial growth factor
  • TGF-beta transforming growth factor
  • It may also be coated with, or the coating may include hyaluronan, hyaluronic acid, glycosaminoglycans (GAGs), Heparin, or amino acids for cell attachment sites, and anti-oxidants such as super oxide dismutase or ascorbic acid.
  • the fabric can be coated with one or more layers (completely or partially) which are composed of one or more bio-absorbable/biodegradable polymers such as, without limitation: poly-glycolic acid; poly-L-lactic acid; copolymers of poly-glycolic acid and poly-L-lactic acid; polycaprolactone; poly-DL lactic acid; polytrimethylene carbonate; polydioxanone; poliglecaprone; and polyglactin, as well as blends, mixtures and copolymers of the foregoing. It may be important that, for example, tissue ingrowth onto a surface be delayed.
  • bio-absorbable/biodegradable polymers such as, without limitation: poly-glycolic acid; poly-L-lactic acid; copolymers of poly-glycolic acid and poly-L-lactic acid; polycaprolactone; poly-DL lactic acid; polytrimethylene carbonate; polydioxanone; poliglecaprone; and polyglactin, as
  • the coating may include an API that is released gradually. Taxol and other drugs have been released from coated stents in a like manner for a variety of reasons, including mitigating the initial stress of placement of the stent. But it may be that an uncoated fabric in contact with the annulus of a heart valve, for example, might be otherwise desirable, such as to allow cell ingrowth to fix the valve in place.
  • a thin outermost layer of a cuff material of the disclosure for example made of one or more bio-absorbable/biodegradable polymers, could facilitate drug release, then get out of the way.
  • FIG. 20 is an exploded view of an exemplary coated fabric 400 in accordance with the present disclosure useful for discussing its general structure in a non-limiting fashion.
  • a completely coated fabric 400 can be created by heat laminating polymer film layers 402 to fabric 404.
  • a single fabric layer 404 may be covered on only one side by a single polymer film layer 402, or the fabric layer 404 may be sandwiched between polymer film layers 402, one or two on each side of the fabric (the latter is illustrated). More complex partially coated constructs of coated fabric 400 are also possible. (See FIGS.
  • Two fabric layers 404 may sandwich a single or multiple polymer film layers 402 and an outer surface of at least one of the two fabric layers 404 may be covered with another polymer film layer 402.
  • polymer film and “polymer film layer” herein is not intended to be limited to the application of one or more discrete preformed polymer films to the fabric, but also includes one or more layers of polymer formed directly on the fabric, such as by dip coating, spray coating, 3-D printing and the like.
  • up to 20 layers of polymer film may be applied to one or to each side of the fabric layer.
  • 1 to 10 layers of polymer film may be applied to one or to both sides of the fabric layer.
  • 1 to 5 layers of polymer film may be applied to one or to both sides of the fabric layer.
  • each side of the fabric layer can be covered, completely or partially, by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 polymer film layers.
  • the various layers need not each have the same thickness or, as noted previously, the same composition or orientation. While even thicker coatings are possible, generally speaking, the thickness of the coating on each side, whether comprised of 1 layer or 20, may range from about 0.5 pm to about 100 pm, in another embodiment from about 0.5 pm to about 50 pm, and in some further embodiments from about 10 pm to about 40 pm. In one other embodiment, the thickness of the coating on each side may range from about 15 pm to about 30 pm. Very thin polymer layers, i.e., from about 0.50 pm to about 2 pm, may be applied simply to fill the open pores in the fabric or for other reasons.
  • a resultant coated fabric in accordance with the disclosure often will be thicker than an uncoated fabric.
  • the overall thickness of a coated fabric could be as high as about 500 pm, or even higher (about 1,000 pm), depending on the fabric being used, the type and number of coatings, and the intended use of the fabric. If the coating is being applied just at or adjacent the attachment edge of a leaflet such that it can be sewn through when attaching the leaflet to a cuff and/or stent, it can be relatively thicker as it will not impact the flexibility of the balance of the leaflet.
  • the thickness of the leaflet could also vary along a gradient, such as from the attachment edge to the free edge of the leaflet.
  • the coated fabric will have a maximum thickness in some embodiments of no more than about 500 pm, in other embodiments of no more than about 250 pm, and in still other embodiments of no more than about 200 pm.
  • the thicknesses of the polymer film layers and the coated fabric are dictated by a balancing of properties and functionality.
  • the number of layers of polymer film applied to the fabric can have an impact on the size to which a collapsible medical device, such as a collapsible prosthetic heart valve, can be collapsed.
  • a collapsible medical device such as a collapsible prosthetic heart valve
  • collapsibility is not a factor dictating thickness.
  • other properties may dictate composition, number of layers and thickness, such as, without limitation, rigidity, porosity, stability and flexibility.
  • Leaflets, cuffs, or other structures of medical devices may be reinforced, weighted, or have their flexibilities altered, or their three dimensional shape established or preserved by the addition of other features, with or without coatings. That is to say that in addition to coatings or partial coatings or layers, structures such as sutures, wires, denser weaves and the like may also be used for these purposes.
  • One such structure that could be used is a suture. A suture could be attached in any number of ways and any number of locations.
  • a single stitch could be placed in the middle of a major surface of the leaflet, or in a specific location on the free edge.
  • a series or pattern of a plurality of individual stitches could be used as well. These could provide reinforcement, could alter the flexibility, or provide weight in order to, for example, bias the leaflet into a proper closed position.
  • One or more sutures could be used to form a one or a plurality of suture lines across an entire major surface or a portion of the major surface of a leaflet, including for example along the attachment edge or along the free edge of the leaflet for any of the reasons just described.
  • a row of sutures could be added, of varying number of stiches, in a line or specified shape, across the full length of the leaflet in a single row from the attachment edge to the free edge of a leaflet.
  • a suture line or suture lines could be spaced from but roughly parallel the free edge as well such as shown in FIG. 67 A or could be spaced apart from but run roughly parallel to the attachment edge as shown in FIG. 67B
  • This row or suture line could be a continuous or discontinuous row. Where more than one suture line is used, one could be continuous and another discontinuous.
  • the properties of the leaflet in this example can be altered based on the number and density of stiches, the number of sutures applied and the location and pattern in which it (they) are applied.
  • leaflets and cuffs are often sutured to each other and/or to a stent. Frequently, as few sutures as required are used for this attachment, and in some instances a single suture could be used to attach each of the leaflets. Using a suture in this fashion, the suture is stitched a plurality of times - sometimes 10’s or even 100’s of times - through the leaflet. Each of these is obviously a stitch. But, a “stitch” in this instance refers to a single stitch or knot of a suture material not used to attach any portion of the leaflet to a cuff, etc.
  • a suture line in this instance is a suture stitched a plurality of times through a cuff or leaflet also not primarily intended to attach the cuff or leaflet to another structure.
  • a “continuous” suture line refers to a single suture line formed from a single continuous suture, or multiple sutures that are substantially continuous with one another (e.g. the first suture ends where the second suture beings).
  • a “discontinuous” suture line refers to a suture line formed of two or more sutures, where the sutures are substantially discontinuous with one another (e.g. the second suture begins at a spaced location from where the first suture ends).
  • One or more sutures could also be stitched to at least a portion of the attachment edge and/or the free edge of a leaflet to provide reinforcement and/or weight and/or to introduce or preserve a shape.
  • the use of sutures here could provide additional strength in an edge that could be sutured or otherwise attached to a cuff and/or stent and can help retard fraying or delamination at the edge.
  • These suture lines could be formed of one or more sutures, can be continuous or discontinuous, and can either be extended in a narrow area or across the entire length of one of these edges.
  • denser weave instead of or in addition to a coating and/or a suture, localized portions of denser weaves can be used for the purposes just described, using a leaflet as an example - at the attachment edge, the free edge, and/or across at least a portion of the face.
  • the phrase “denser weave,” “increased weave density,” or similar terms refer to a fabric having a weave with more fabric per unit area or per unit volume compared to other areas of the weave.
  • those portions with the increased weave density may be formed by introducing more fabric in that area during formation of the fabric leaflet, or otherwise after the fabric leaflet is formed with a uniform weave density.
  • additional fabric material may be woven into area where it is desired to increase weave density, or additional pre -woven material may be added onto the fabric leaflet, for example a swatch of fabric may be coupled to the fabric leaflet in areas where it is desired to increase weave density.
  • the wire or other reinforcement may extend across the entire edge, just a portion of it, may be continuous or discontinuous.
  • a “continuous” or “discontinuous” wire has a similar definition as the continuous or discontinuous suture line described above, except the reference material is a wire instead of a suture.
  • a suture could be used instead of a wire, or other fiber which is attached by being glued or laminated between the fabric and a layer or partial layer instead of being stitched.
  • the medical device, or an element thereof, such as a fabric leaflet could be constructed or attached so as to form a pleat or fold across a major surface of the leaflet.
  • this can be accomplished by suturing a gathering of the fabric at the attachment edge and optionally by including structures, cuts or ablations on a major surface of the leaflet in order to form folding zones or pleats.
  • Producing coated fabrics may be accomplished by any known method. U.S. Patent No.
  • U.S. Patent No. 4,610,918 describes the production of fluoropolymer coated textiles and U.S. Patent No. 7,109,135 relates to a woven fabric sandwiched between PTFE layers.
  • the polymer layers may be extruded via any extrusion mechanism known to those of skill in the art and applied or laminated to fabrics using heat and pressure, such as rollers.
  • polymer layers may be bonded to fabric layers using an adhesive or adhesion promoting agent.
  • the polymer layers may also be formed in situ by spray coating or dip coating the fabric layers, or a side thereof, with a polymer that will dry, or that can be cross-linked, to form a layer or layers.
  • the coatings and partial coatings may also be applied by 3D printing.
  • the coated fabric may also include intermediate materials or layers intended to improve adhesion between the polymer layers and the fabric layers.
  • FIGS 21-23, 34-42 and 47-67B illustrate certain exemplary structures that can result from the formation of a partial coating.
  • the partial coatings forming these structures can, of course, be applied to a fabric layer in a manner similar to complete coatings.
  • polymer films of the desired shape and size can be placed where desired and glued, laminated, etc. in place; liquid polymer can be molded to the shape desired; or an edge of the fabric can be dip coated.
  • a partial coating may also be achieved by fully coating a major surface of the fabric layer (or a partially or fully coated fabric layer) and then removing unwanted portions of that coating or unwanted portions of specific layers by ablating, melting, evaporating, cutting, eroding or frictionally removing (sanding, grinding, rubbing).
  • ribs, reinforced areas adjacent an attachment region, and structures at or adjacent the free edge used to resist wear can ah be formed by removing the coating material between those structures.
  • Ablation can also be used to provide a pattern in a coated surface or to impart other surface features.
  • Ablation could be used, for example, to taper the thickness of a leaflet, just for example, from an attachment edge to the free edge. This is accomplished by progressively ablating the coating layer(s) from one edge to the other, deeper and deeper, thus removing more and more of the coating.
  • ablation could be used to remove a portion of the coating(s) in a selected area, such as in the portion of a leaflet that will form its belly when in use in a heart valve, to provide additional flexibility to that region.
  • Other surface patterns may also be developed.
  • surface roughening such as to promote cell adhesion generally or in specific areas of the surface, may be employed.
  • the top most layers that will be selectively ablated could be composed of one polymer material, with one or more under layers that are not to be removed or patterned being composed of a different polymer material.
  • these processes for removing portions of a full coating have just been described in connection with forming partial coatings, they may also be used to provide patterns and/or surface features in complete coatings where no portion of the major surface of the fabric is substantially uncoated. See, for example, FIG. 37, which contains a full coating 3751 disposed between fiber layer 3740 and an additional coating feature 3750 adjacent the free edge 3730.
  • Layer 3750 could be applied to polymer layer 3571 or it could be formed by ablating away a portion of a top layer leaving only portion 3750.
  • the polymer layer or layers may therefore form a pattern or relief on one or both sides of a fabric layer. They may vary thickness; provide rigidity or additional cohesion to specific regions; retard fraying; reinforce shape, stretch, or friction; alter porosity; provide or encourage cell attachment or prohibit it in specific areas; enhance coaptation; and the like.
  • FIG. 21 illustrates a non-limiting example of a coated fabric 2100 which may be patterned as shown.
  • a fabric layer 2104 may be discontinuously coated with a polymer layer 2103 such that only the area a few millimeters from each edge of the top major surface of the fabric layer 2104 is polymer coated — forming a structure looking like a picture in a frame, as shown in FIG. 21.
  • the bottom major surface of the fabric layer 2104 may be continuously coated with a polymer layer 2102. The reverse may also be possible.
  • a checkerboard pattern, a series of strips, concentric circles or other shapes may be laminated, printed, etched, masked, coated or otherwise formed onto one or more major surfaces of the fabric.
  • Each of these patterns can be formed by using differing thicknesses and/or different numbers of layers of polymer.
  • the entire upper surface of a fabric could be coated.
  • different portions of the surface could be coated with different thicknesses and/or different numbers of layers of polymer. This can be done to provide a coated fabric with areas of greater or lesser porosity, areas of greater or lesser surface irregularity or roughness, areas of different texture, and/or areas of greater flexibility or rigidity.
  • Controlled coating of the fabric may also provide preferred movement or folding, reinforcement of certain areas, greater wear resistance, areas in which it is harder for a tear to form or propagate near a suture, or a combination of any of these.
  • FIG. 22 illustrates another example of a partially coated fabric 2200 in which a fabric layer
  • 2204 may be coated on its entire lower surface with a single polymer layer 2202.
  • two continuous polymer layers 2202 may be applied to the upper surface of fabric layer 2204, and a third polymer layer may be printed or otherwise applied thereto in a discontinuous fashion over the continuous layers.
  • a portion of this third layer may be, in this example, applied to the continuous layers 2202 so as to overlie two opposed edges 2206 and 2208 of the coated fabric 2200. This could be done to reinforce those areas of the coated fabric that may be attached with, for example, sutures, to the luminal and abluminal surfaces of a stent and wrapped around the inflow end of the stent to provide internal and external cuffs.
  • the third layer may include a curved portion 2212 to help reinforce that portion of the resulting inner cuff at which leaflets will likely be attached.
  • the third layer may also include another strip 2210 located in the area of the coated fabric 2200 which will actually wrap around the inflow end of the stent to help prevent abrasion upon contact between the cuffs and the stent and to provide a sturdier portion for suturing to the inflow end of the stent.
  • FIGS. 23A - 23C illustrate a patterned coated fabric for use in a leaflet 2300.
  • the fabric layer 2304 may be discontinuously coated with a polymer layer 2302 such that only the area a few millimeters from each edge of the fabric layer is coated.
  • the pattern as just described may be used for a leaflet in which only the attachment edge and the free edge of the leaflet are coated, as shown in FIG. 23A.
  • the pattern as just described for a leaflet may have a fabric layer discontinuously coated with a polymer layer such that an area extending about 10 mm from the attachment edge and the free edge is coated with the polymer.
  • the coating areas may not be uniform and the fabric 2304 may be coated in an area extending about 10 mm from the attachment edge with polymer 2302a and in an area extending about 5 mm from the free edge with polymer 2302b, as is shown in FIG. 23B and FIG. 23C, respectively.
  • FIG. 23B illustrates the underside (or upstream surface) of the leaflet which attaches to the stent
  • FIG. 23C illustrates the other side (or downstream surface) of the leaflet. The reverse may also be possible when used for a leaflet.
  • FIG. 24 illustrates a coated fabric composed of multiple polymer layers and multiple fabric layers.
  • the fabric layers may be oriented such that their warp fibers either are oriented substantially parallel to the longitudinal edges of the coated fabric (not on a bias), or at a bias of between about 30 degrees and about 60 degrees relative to the longitudinal edges of the coated fabric.
  • the coated fabric with multiple polymer layers and multiple fabric layers may be formed by alternating each polymer layer with a fabric layer such that each fabric layer has a polymer layer on both its top surface and its bottom surface.
  • a first fabric layer 2404a is oriented at about a 45 degree bias relative to the longitudinal edges of the coated fabric, while second fabric layer 2404b is not oriented on a bias.
  • Each fabric layer 2404a, 2404b may be coated with a polymer layer 2402.
  • FIGS. 25 and 26 depict a heart valve leaflet fabricated from a fabric composed of
  • the fabric may be cut to a desired geometry by stamping, mechanical cutting, laser cutting or other known techniques. As shown in FIG. 25, the UHMWPE fabric is cut to produce a heart valve leaflet having fibers 600 oriented at a 45 degree angle relative to the direction from the attachment edge to the free edge of the leaflet.
  • FIG. 26 shows an enlarged portion of the heart valve leaflet of FIG. 25 showing the edge quality of the heart valve leaflet produced by laser cutting. The laser cutting may melt the edges of the leaflets to effectively create a single, continuous seam. There may be a preference for a smooth transition between the main leaflet body and the edges of the leaflet.
  • edges of the leaflet may be coated with a polymer as described above to ensure a smooth transition between the main leaflet body and the edges of the leaflet.
  • At least one of the leaflets may be composed of a woven or knitted fabric that is coated or uncoated and fabricated such that its fibers are at a bias angle of between about 30 degrees and about 60 degrees relative to a line that extends perpendicular to the free edge of the leaflet when the leaflet is in a flattened condition or lies within a plane (e.g., before the leaflet is attached to the valve assembly) .
  • all of the leaflets may be fabricated with their fibers at that same relative bias.
  • the leaflets may not all be fabricated with their fibers at that same bias.
  • all of the leaflets may be fabricated with their fibers on a bias of between about 30 degrees and about 60 degrees relative to a line that extends perpendicular to the free edge of the leaflet, but the fibers of at least one of the leaflets are not on the same bias as the fibers of the other leaflets of the valve assembly.
  • the fibers of at least one such leaflet are biased at between about 30 degrees and about 60 degrees relative to a line that extends perpendicular to the free edge of the leaflet and the fibers of at least one other leaflet are not.
  • FIGS. 28-46A further illustrate the structural diversity of coated and uncoated synthetic fabrics useful in medical devices in accordance with the present disclosure. This diversity is illustrated by using leaflets and cuffs useful in the construction of collapsible/expandable heart valves. It should be understood, however, that these structures are illustrative and that the fabric materials depicted can be used in other medical devices and their shape, thickness, and composition may be adjusted to suit that particular purpose.
  • leaflet 2808 an uncoated leaflet, consists only of a fabric 2840.
  • Leaflet 2808 includes a first major surface or downstream surface 2815 and a second major surface or upstream surface 2820.
  • Leaflet 2808 is similar to leaflet 108 shown in FIG. 2 attached to a stent so as to form a one-way valve assembly.
  • the actual surface illustrated in FIG. 2 is the first major surface or downstream surface as blood flows into the valve from the inflow or annulus end 130 to the outflow or aortic end 132. Blood flows from upstream to downstream and, accordingly, the first major surface is considered the downstream side with the downstream surface 2815 and the opposite major surface is the upstream surface 2820.
  • downstream surface 2815 is the major surface generally facing the outflow or aortic end 132 of the stent when the valve leaflets are in a closed position during use.
  • the upstream surface 2820 generally faces the inflow or annulus end 130 of the stent when the leaflets are in the closed position.
  • Leaflet 2808 has a free edge 2830, an attachment edge 2825, and a plurality of tabs or flaps 2835.
  • the leaflet is attached to the cuff and/or to the stent at or adjacent the attachment edge 2825.
  • the tabs 2835 often form commissures at which two adjacent leaflets meet.
  • Each tab 2835 is often attached to an adjacent tab of an adjacent leaflet and/or to the stent at, for example, a commissure attachment feature such as element 116 in FIG. 2. While much of the fabric moves during operation of the prosthetic heart valve, the greatest degree of movement is experienced by the free edge 2830. It is pushed out of the way from the center of the valve toward the luminal surface of the stent when blood is flowing, and is pushed back toward the center of the valve where it engages or coapts with other leaflets when the valve is closed.
  • the fabric leaflet 2808 in FIG. 28 is uncoated, and it can be composed of any uncoated at least partially synthetic fabric as disclosed herein.
  • Leaflet 2808 is illustrated as a single layer of fabric, although multiple layers of fabric could be stacked directly atop one another and attached to one another by suitable methods, such as gluing, stitching, spot welding, and the like.
  • FIG. 29 illustrates a coated fabric and is generally of the same structure and composition as that illustrated in FIG. 28, other than the coating.
  • the leaflet 2908 in FIG. 29 includes a fabric layer 2940, which can be composed of any of the fabrics disclosed herein, as well as a polymer layer 2945.
  • polymer layer 2945 is generally coextensive with the shape and size of fabric layer 2940 and is attached to the upstream surface 2920 of the fabric layer.
  • Fabric layer 2940 and polymer layer 2945 are illustrated as being of roughly the same thickness, however, that need not be the case. Multiple fabric layers and/or multiple polymer layers are possible and contemplated as described elsewhere herein.
  • the leaflet 2908 in FIG. 29 is illustrated with the downstream surface not covered by a polymer layer. It can, however, be covered by one or more polymer layers as well. Indeed, this concept is illustrated in FIG. 30.
  • FIG. 30 illustrates a valve leaflet 3008 as generally described in FIGS. 28 and 29 comprised of a fabric layer 3040, a first polymer layer 3045 covering the entire upstream surface of the fabric layer and a second polymer layer 3050 covering the entire downstream surface of the fabric layer.
  • the individual layers can be made of any of the fabrics and any of the polymer coating materials described herein. While a leaflet having three layers is illustrated, more layers are possible, and the layers may be of varying thicknesses.
  • FIG. 31 illustrates a leaflet 3108 as described in connection with FIGS. 28-30.
  • Leaflet 3108 has a multilayered structure in which the fabric layer 3140 is coated on both of its major surfaces with at least one polymer layer.
  • Leaflet 3108 contains a fabric layer 3140 as discussed herein, and a single polymer layer 3145 covering the entire upstream surface of the fabric layer. There are, however, three polymer layers covering and attached to, directly or indirectly, the entire downstream surface of leaflet 3108.
  • the most downstream or outermost layer 3150 may be made of ultra-high molecular weight polyethylene (UHMWPE), the next adjacent layer 3151 may be made of low density polyethylene, and the third and final layer 3152 situated against the fabric layer 3140 may also be composed of UHMWPE.
  • UHMWPE ultra-high molecular weight polyethylene
  • the next adjacent layer 3151 may be made of low density polyethylene
  • the third and final layer 3152 situated against the fabric layer 3140 may also be composed of UHMWPE.
  • polymer layer 3145 disposed on the upstream surface of fabric layer 3140. This need not be the case.
  • Each of the individual polymer layers may be thin or thick and their combination may be thicker or thinner than polymer layer 3145 or fabric layer 3140.
  • the number of layers that can be applied to any one major surface of the fabric layer can be as many as 20 layers.
  • FIG. 32 shows another construction of a leaflet generally discussed and illustrated in
  • Leaflet 3208 includes two fabric layers separated by, and each attached to, a polymer layer disposed between them. Specifically, fabric layer 3240 forms a downstream side of leaflet 3208 and fabric layer 3255 forms the upstream side of the leaflet. Fabric layers 3240 and 3255 may be the same as one another, or may be different from one another in composition, thread count, fiber orientation, weave pattern, thickness, etc. A polymer layer 3245 is disposed between and is coextensive with the second (upstream) major surface of fabric layer 3240 and the first (downstream) major surface of fabric layer 3255.
  • Fabric layers 3240 and 3255 may be the same as or different from one another in composition, structure, thickness, etc., and each may be a single layer or multiple layers independently of one another. While a single polymer layer 3245 is illustrated between the fabric layers, this layer could be composed of multiple polymer layers having the same or different structures, thicknesses, and compositions.
  • FIG. 33 illustrates yet another possible construction of a fabric leaflet, as generally described in connection with FIGS. 28-32.
  • Leaflet 3308 is constructed with two fabric layers 3340 and 3355, and a polymer layer 3345 disposed between them. Additionally, the downstream surface of fabric layer 3340 is covered with a polymer layer 3350 and the upstream surface of fabric layer 3355 of leaflet 3308 is also covered with a polymer layer 3360.
  • Fabric layers 3340 and 3355 may be the same as one another, or may be different from one another in composition, thread count, fiber orientation, weave pattern, thickness, etc.
  • polymer layers 3345, 3350 and 3360 may be the same as one another or may be different from one another in structure, composition, thickness, etc.
  • FIG. 34 illustrates a partially coated leaflet 3408.
  • Leaflet 3408 comprises a fabric layer 3440. Any fabric described in accordance with the disclosure may be used.
  • Leaflet 3408 also includes a partial polymer coating 3450 disposed as a single layer on its downstream surface 3415 adjacent the free edge 3430 of the leaflet. This partial polymer layer 3450 is illustrated as being the same width as tabs 3435 and roughly the same thickness as fabric layer 3440. Flowever, that need not be the case. Polymer layer 3450 may be wider or narrower across the downstream face 3415 of fabric layer 3440 and may be thicker or thinner than the fabric layer. That said, layer 3450 is often thinner than and not as wide as the fabric layer. Multiple polymer layers and fabric layers may be used as opposed to the single layers illustrated.
  • the partial coating 3450 adjacent the free edge 3430 of leaflet 3408 may serve one or more purposes. For example, it may help add weight to bias the leaflet back into a closed position, it may help the leaflet retain its intended shape, and may promote or prevent cell attachment and proliferation adjacent the free edge 3430.
  • FIG. 34A is a partial cross-section of a stent and a valve assembly similar to those shown in FIG. 2.
  • a portion of the stent 3402 is illustrated in cross-section with an internal cuff 3406 attached to a luminal surface of the stent.
  • Leaflet 3408 is attached to cuff 3406 and/or stent 3402 at or adjacent its attachment edge 3425, which may be sutured to the cuff and/or stent.
  • Leaflet 3408 is illustrated in its open position as it extends generally downstream to accommodate blood flow from the inflow end of the stent to the outflow end past the upstream surface 3420 of the leaflet.
  • Partial coating 3450 is disposed on the downstream surface 3415 of the leaflet edge adjacent the free edge 3430 of fabric layer 3440 and is illustrated engaging the luminal surface of stent 3402. Partial coating 3450 therefore prevents direct contact of the fabric layer 3440 and any layer disposed on the downstream surface of the fabric layer with the inner surface of the stent during blood flow, thereby providing additional wear resistance and helping to prevent the fraying of the free edge 3430 of the fabric layer. In addition to providing resistance to wear, such partial coating 3450 could also help maintain the shape of the leaflet and its ability to coapt with other leaflets, despite cell ingrowth on the downstream surface 3415 of the leaflet. Without partial coating 3450, inter cellular attachment could exert forces that could tend to pull the free edge out of proper position.
  • a similar partial coating may be applied to the upstream surface 3420 of the leaflet, adjacent the free edge 3430 or otherwise, to resist the deformation of the leaflet due to cellular ingrowth.
  • Partial polymer layer 3450 is shown extending fully across the entirety of the free edge 3430 of leaflet 3408 between tabs 3435. This need not be the case. Partial polymer layer 3450 may be provided adjacent free edge 3430 but not overlying tabs 3435. Further, partial polymer layer 3450 may be a discontinuous layer of two, three, or more coated portions forming in essence a dashed line adjacent free edge 3430. Still further, layer 3450 may be formed of spots or dots formed intermittently adjacent free edge 3430. Each dot or each dash may have a different thickness and/or may be composed of a different composition.
  • FIG. 35 illustrates another embodiment of the fabric leaflets generally illustrated in
  • FIGS. 28-34 Leaflet 3508 includes a fabric layer 3540 and a polymer layer 3545 disposed on its upstream surface 3520. Polymer layer 3545, however, does not cover the entirety of the upstream surface 3520 of fabric layer 3540. It is a relatively narrower layer in width and runs adjacent the attachment edge 3525, extending inwardly therefrom for some predefined width. An illustrative width is shown using the dashed semicircular line 3560 in FIG. 35.
  • FIG. 35A is a partial cross-section of a stent 3502 and a valve assembly similar to those illustrated in FIG. 2. Attached to a luminal surface of stent 3502 is a cuff 3506.
  • Leaflet 3508 as shown is composed of fabric layer 3540, which is rolled or folded adjacent its attachment edge 3525 for attachment purposes. Disposed between fabric layer 3540 and cuff 3506 is polymer layer 3545, which is provided adjacent the attachment edge 3525 of fabric layer 3540. As is true for FIG. 34A, leaflet 3508 is illustrated in the open position, e.g., a position that would be roughly when blood is flowing through the valve from the inflow end of the stent to the outflow end. Leaflet 3508 may be attached via a suture 3503 anchoring both fabric layer 3540 and polymer layer 3545 to cuff 3506 and/or stent 3502.
  • the partial layer 3545 need not be a single layer nor need it be the same thickness or composition as fabric layer 3540. As was previously described, its width need not extend over the entire upstream surface 3520 of fabric layer 3540. Indeed, generally, it may be provided with sufficient width only to allow a suture therethrough. Partial layer 3545 may provide additional reinforcement and/or may help prevent fraying when suturing leaflet 3508 to cuff 3506 and/or stent 3502. It may serve other purposes as well.
  • Partial polymer layer 3545 is illustrated as being disposed on the upstream surface 3520 of fabric layer 3540. However, it may be disposed on the downstream surface or on both the upstream and downstream surfaces to provide additional reinforcement and/or other advantages. Partial layer 3545 also is illustrated as covering the entire attachment edge and tabs of leaflet 3508. That need not be the case. It need not be provided at the tabs and/or may be provided as discontinuous dashes or spots of varying compositions, number of layers and thicknesses as previously discussed in connection partial layer 3450 in FIG. 34.
  • FIG. 36 is an amalgam of the leaflets illustrated previously in FIGS. 34 and 35. It includes a fabric layer 3640 having attached to its downstream surface 3615 a partial polymer layer 3650 adjacent its free edge 3630. It also includes a partial polymer layer 3645 on the upstream surface 3620 of fabric layer 3640 adjacent the attachment edge 3625.
  • FIG. 37 illustrates another embodiment of a leaflet such as described in FIGS. 28-36.
  • Leaflet 3708 includes a fabric layer 3740 having a polymer layer 3751 applied to its entire downstream surface 3715. Adjacent the free edge 3730 is a further partial polymer layer 3750 applied atop/upon layer 3751. Partial layer 3750 may be any layer as previously described, such as, for example, partial layer 3450 in FIG. 34.
  • Leaflet 3708 also includes a partial polymer layer 3745 attached to the upstream surface 3720 of fabric layer 3740 adjacent the attachment edge 3725, generally as described for partial polymer layer 3545 in FIG. 35.
  • the width of polymer layer 3745 adjacent the attachment edge 3725 is much greater than the width of polymer layer 3750 adjacent the free edge 3730 of leaflet 3708. This is meant merely to illustrate the fact that there are partial layers on various surfaces of a leaflet and that they may independently have different widths.
  • FIG. 38 illustrates another embodiment of a leaflet 3808 generally as described in
  • Leaflet 3808 contains a fabric layer 3840 similar to the fabric layers previously described. Disposed on the downstream surface 3815 of the leaflet are one or more “ribs” or reinforcing strips 3850 composed of a partial polymer layer. These ribs are shown as running from approximately the attachment edge 3825 to the free edge 3830 of leaflet 3808. Reinforcing ribs 3850 may provide weight and structure to bias the leaflet from an open position back to a closed position. They may also provide some measure of structural rigidity and reinforcement to leaflet 3808. While shown as extending from the attachment edge 3825 of the leaflet to the free edge 3830, that may not be the case. They may extend from attachment edge 3825 approximately halfway along the downstream surface 3815 of the leaflet toward the free edge 3830. Similarly, they may extend from adjacent free edge 3830 approximately 30% of the way along the downstream surface of fabric layer 3840 toward the attachment edge 3825. Ribs 3850 may be of any length, thickness, width, number of polymer layers and composition.
  • ribs 3850 are shown applied to the downstream surface 3815 of fabric layer 3840, they could be applied to the upstream surface 3820 thereof instead of, or in addition to, their application to the downstream surface. Moreover, the entire downstream surface of the leaflet in FIG. 38 may be coated with an additional polymer layer (not shown) to provide a smooth, if undulating, surface topography. A similar polymer layer could be provided on the upstream surface of the leaflet if ribs 3850 were applied to upstream surface 3820.
  • leaflet 3908 contains a plurality of ribs 3950 again extending from adjacent the attachment edge to the free edge of fabric layer 3940.
  • the spaces 3975 between ribs 3950 may act as folding regions helping to provide a controlled fold of the leaflet when the prosthetic heart valve is collapsed for loading into a catheter for transcatheter or transapical delivery.
  • leaflet 3908, or any leaflet described herein, whether coated or uncoated may be scored on its upstream surface or downstream surface, such as with a laser, to produce a pattern on the surface. Such pattern may facilitate folding of the leaflet during collapsing of the prosthetic heart valve, may increase the flexibility of the leaflet for opening and closing during use, or may improve the performance of the leaflet in other ways.
  • FIG. 40 illustrates another leaflet embodiment.
  • leaflet 4008 comprises a fabric layer 4040 having a downstream surface 4015 to which are attached one or more polymer dots or spots 4050.
  • the spots 4050 may provide weight to help bias the leaflet to a closed position in operation.
  • Spots 4050 may also provide selective reinforcement and/or abrasion resistance. While shown as spots or dots in FIG. 40, these spots could be present in any number and in any shape such as, without limitation, crosses, lines, dashes, polygons, etc.
  • FIGS. 41, 41 A, and 41B illustrate other partial coating arrangements for a leaflet.
  • partial polymer coatings are disposed on the downstream surface 4115 of the fabric layer 4140 of leaflet 4108.
  • a first semicircular polymer coating area 4150 of a predetermined width may be comprised of five individual polymer layers, which may be the same or different in composition and thickness.
  • Disposed relatively inwardly toward the free edge 4130 of leaflet 4108 is a second concentric semicircular partial coated area 4151 comprised of three different polymer layers. These layers may have the same composition and thickness or a different composition and/or thickness from those used in partial coated area 4150. They may have the same or a different width as well.
  • Finally, further inwardly and closer free edge 4130 is partial coated area 4152 composed of a single polymer layer.
  • Partial coated area 4152 may be made of one of the polymers used in partial coated areas 4150 or 4151 or may be made of a different material altogether. It may have a width that is the same as or different from areas 4150 and 4151. The area directly adjacent free edge 4130 in this embodiment is uncoated. This entire structure could be coated with an additional continuous layer that would provide a smoother surface, albeit one gradually getting thinner from the attached edge 4125 to free edge 4130.
  • FIG. 41 A shows a similar construction, however, coating area 4151 is disposed on the upstream surface 4120 of the leaflet as opposed to the downstream surface 4115. Partial coated area 4150 composed of five individual polymer layers and partial coated area 4152 composed of a single polymer layer are disposed on the downstream surface 4115.
  • FIG. 41B shows a similar construction, however, instead of being semicircular or forming a rainbow, the coated areas are formed in parallel strips, with the first strip 4150 running roughly parallel to the free edge 4130 composed of five individual polymer layers, the next strip 4151 composed of three layers and the last area 4152 composed of a single layer.
  • FIG. 42 illustrates a partial coating on a fabric leaflet 4208 disposed on the upstream side of the leaflet.
  • leaflet 4208 is shown comprising a fabric layer 4240 and applied to its upstream surface 4220 is a reinforcing partial polymer coating 4245.
  • This structure is made of a partial coating of at least one polymer layer, and possibly a plurality of polymer layers, in any shape or size as described in FIGS. 28-41.
  • the leaflet 4308 in FIGS. 43 and 43 A is similar in structure to a leaflet described in connection with FIG. 29, except that the polymer layer 4350 is disposed on the downstream surface 4315 of fabric layer 4340.
  • Leaflet 4308 contains one or more indicia 4380 that may be apparent visually to the naked eye, may be radiopaque to make it visible during surgery when the device is implanted within a patient’s anatomy, or both.
  • Indicia 4380 may help a surgeon position and orient the valve as needed and may assist in visualizing the movement of the leaflet to show an operable valve. Letters are used as the indicia 4380 in FIG. 43, but numbers, Roman numerals, symbols, or any other relevant indicia may be used as well.
  • 43 A is a view of a coapted set of leaflets such as shown in FIG. 3. It illustrates the use of a plurality of indicia 4380 individually on each leaflet 4308.
  • the indicia may be embedded within polymer layer 4350, may be sandwiched between adjacent polymer layers, or may be disposed between polymer layer 4350 and fabric layer 4340.
  • FIGS. 44, 44A, 44B, and 44C illustrate an embodiment similar to that shown in FIG. 43.
  • Leaflet 4408 is an uncoated fabric composed entirely of fabric layer 4440. Woven into that fabric, melted or otherwise embedded into the fabric, or glued or otherwise applied to a surface of the fabric may be visual and/or radiopaque indicia 4480.
  • FIG. 44A shows an embodiment like that shown in FIG. 43A, in which indicia 4480 constitute a plurality of letters.
  • FIG. 44B shows indicia 4480 as Roman numerals, and
  • FIG. 44C shows the indicia as a series of dots.
  • FIGS. 45, 45 A and 45B illustrate a leaflet as previously described in connection with
  • Leaflet 4508 includes a fabric layer 4540 and attached to its upstream surface 4520 adjacent attachment edge 4525 is a polymer layer 4545, which partially coats the upstream surface 4520 of the fabric layer. Additionally, leaflet 4508 includes a number of holes 4590 disposed adjacent attachment edge 4525 and through both fabric layer 4540 and partial polymer layer 4545. These holes 4590 may facilitate suturing, lacing or other attachment of leaflet 4508 to the support structure. Floles 4590 may also be formed in the leaflet tabs 4535 to facilitate the attachment or lacing of the leaflet commissures to one another by aligning the holes in adjacent leaflet tabs, as well as the attachment of the leaflets to the stent.
  • Floles 4590 may be formed by laser drilling, a process that locally melts the polymer fabric and polymer layer forming a smooth, tough, abrasion resistant surface, much like a grommet, that can provide resistance to damage caused by the passage of sutures therethrough during the suturing process.
  • These holes or grommets 4590 may be coated with a more lubricous coating or polymer material that is permanent or one that can be removed to further improve the suturing process and prevent damage to the leaflet.
  • the laser drilling process may melt the various layers together in a localized area, which could help prevent fraying or damage. While laser drilled holes have been described, the holes may be produced by any other means as well, such as molding, mechanical or water jet drilling, and the like.
  • FIG. 45A shows a partial cross-sectional view of a stent with an attached valve assembly as previously described.
  • stent 4502 has a cuff 4506 attached to its luminal surface.
  • Leaflet 4508 composed of fabric layer 4540 contains a partial polymer layer 4545 on its downstream surface 4515, which is disposed between the cuff and the fabric layer 4540.
  • Leaflet 4508 contains grommets 4590 through which the leaflet is sutured or laced to cuff 4506, stent 4502, or both. Grommets may also be formed in a pattern in cuff 4506 to facilitate the attachment of the cuff to the stent.
  • FIG. 45B shows a similar arrangement in which the device contains no cuff and a partial polymer layer 4545 is disposed on the upstream side 4520 of leaflet 4508, as illustrated in FIG. 45.
  • Grommets 4590 are provided through both fabric layer 4540 and partial polymer layer 4545, enabling the leaflet to be sutured or laced via suture 4503 to the stent 4502.
  • Grommets have been described here in connection with partially coated leaflets. However, these grommets could be formed in fully coated or completely uncoated leaflets, in coated or uncoated cuffs, and in any portion of a medical device that may be attached to a support structure by a suture.
  • FIG. 46 illustrates a stent 4602 containing a cuff 4606 on its abluminal or exterior surface.
  • Cuff 4606 contains a plurality of indicia, in this case, radiopaque bands 4680 disposed at various intervals to assist the surgeon in placement of the prosthetic valve.
  • the structure of cuff 4606 is illustrated in more detail in FIG. 46A. Attached to the exterior of stent 4602, and provided for illustrative purposes only, cuff 4606 has four layers.
  • the outermost layer 4691 is a polymer layer covering the entire exterior surface of cuff 4606.
  • the next innermost layer is a fabric layer 4692. Disposed between the fabric layer 4692 and outermost polymer layer 4691 are the circumferential radiopaque and/or visual indicia 4680.
  • Between the fabric layer 4692 and stent 4602 are two additional polymer layers 4693 and 4694.
  • Each of layers 4691, 4693 and 4694 may be composed of the same or different polymer materials or may have the same or different dimensions and thicknesses as previously described in connection with the leaflets described in FIGS. 28-45.
  • FIG. 47 shows a leaflet 4710 formed from a woven fabric according to the present disclosure including a single stitch 4720 disposed through a major surface 4730 of the leaflet.
  • FIG. 48 shows a leaflet 4810 of a leaflet formed from a fabric according to the present disclosure including a single stitch 4820 in the free edge 4830 of the leaflet.
  • FIG. 49 shows a leaflet 4910 of a leaflet formed from a fabric according to the present disclosure including multiple stitches 4920 on a major surface 4930 of the leaflet.
  • FIG. 50 shows a leaflet 5010 formed from a fabric according to the present disclosure including multiple stitches 5020 along the free edge 5030 of the leaflet.
  • Leaflet 5010 is illustrated with a partial or complete coating and/or layer positioned on one major surface of the fabric layer. Stitches 5020 may pass through the fabric, the coating, or both.
  • FIG. 51 shows a leaflet 5110 formed from a fabric according to the present disclosure including a suture line 5120 extending across a major surface 5130 of the leaflet from the attachment edge 5140 to the free edge 5150.
  • Leaflet 5110 is illustrated with a partial or complete coating and/or layer positioned on the fabric as noted in FIG 50.
  • Suture line 5120 may pass through the fabric, the coating, or both.
  • FIG. 52 shows a leaflet 5210 formed from a fabric according to the present disclosure including a plurality of suture lines 5220 extending across a major surface 5230 of the leaflet from the attachment edge 5240 to the free edge 5250.
  • FIG. 53 shows a leaflet 5310 formed from a fabric according to the present disclosure including a discontinuous suture line 5320 extending across a major surface 5330 of the leaflet from the attachment edge 5340 to the free edge 5350.
  • Leaflet 5310 is illustrated with a partial or complete coating and/or layer positioned on the fabric.
  • Suture line 5320 may pass through the fabric, the coating, or both.
  • the use of discontinuous sutures can create regions of relatively greater and lesser flexibility along the suture line.
  • FIG. 54 shows a leaflet 5410 formed from a fabric according to the present disclosure including a suture line 5420 extending along the free edge 5450 of the leaflet.
  • Leaflet 5410 is illustrated with a partial or complete coating and/or layer positioned on the fabric.
  • Suture line 5420 may pass through the fabric, the coating, or both.
  • FIG. 55 shows a leaflet 5510 formed from a fabric according to the present disclosure including a discontinuous suture line 5520 extending along the free edge 5550 of the leaflet.
  • FIG. 56 shows a leaflet 5610 formed from a fabric according to the present disclosure including a suture line 5620 extending along the attachment edge 5640 of the leaflet.
  • this suture line can in addition or instead provide benefits in attaching the leaflet by providing reinforcement through which attachment sutures will pass. It could also assist in preventing the fabric from unravelling over time,
  • FIG. 57 shows a leaflet 5710 formed from a fabric according to the present disclosure including a discontinuous suture line 5720 extending along the attachment edge 5740 of the leaflet.
  • Leaflet 5710 is illustrated with a partial or complete coating and/or layer positioned on the fabric.
  • Suture line 5720 may pass through the fabric, the coating, or both. As also described in connection with other suture lines, the gaps here can provide regions of relative flexibility.
  • FIG. 58 shows a leaflet 5810 formed from a fabric according to the present disclosure including a suture line 5820 extending along the free edge 5850 of the leaflet through a partial coating layer 5860 as well as the fabric layer it covers.
  • FIG. 59 shows a leaflet 5910 formed from a fabric according to the present disclosure including a suture line 5920 extending along the free edge 5950 of a leaflet, the suture line being disposed underneath a partial coating layer 5960 and laced through the polymer fabric.
  • FIG. 60 shows a leaflet 6010 formed from a fabric according to the present disclosure including an area of increased weave density 6020 extending along and adjacent the free edge 6050 of the leaflet. The area of increased weave density 6020 has higher weave density compared to the remaining portions of the fabric leaflet 6010. This can provide many of the same functions and advantages as just described for suture lines,
  • FIG. 61 shows a leaflet 6110 formed from a fabric according to the present disclosure including an area of increased weave density 6120 extending along the attachment edge 6140 of a leaflet.
  • the area of increased weave density 6120 has higher weave density compared to the remaining portions of the fabric leaflet 6110. This can provide many of the same functions and advantages as just described for suture lines,
  • FIG. 62 shows a leaflet 6210 formed from a fabric according to the present disclosure including a pleat formed therein.
  • the pleats are formed by fold lines 6270, 6280.
  • Fold lines 6270 are folds in which the vertex is pointed in first direction which is visible in Fig. 62, with fold lines 6280 having the vertex pointed in the opposite direction.
  • the pleats formed by the fold lines 6270, 6280 may unfold when a load is exerted on the leaflet 6210 during loading and may reform during valve opening.
  • the pleats may be formed by folding a first portion of the fabric over a second portion of the fabric. The ultimate goal of using one or more pleats may be to reduce strain in the leaflet 6210.
  • the pleats can be folded into the leaflet 6210 such that they fully expand to their original structure once deployed.
  • the pleats may be formed in any suitable fashion.
  • the fabric material may be gathered and/or folded to form a pleat, with the material being tacked down using a suture or grommet such that while expanded, the pleat maintains its shape to some degree.
  • Pleats may also be facilitated by scoring or partial ablation (e.g. via a laser). If the pleats are tacked down, it may be preferable to tack the pleats only at the ends of the pleat, although in some circumstances the pleats may be tacked down in other or additional locations, such as along a middle portion of the pleat.
  • the fold lines 6270, 6280 forming the pleats generally extend from the attachment edge 6240 to the free edge 6250, although other locations and/or directions of the pleats may be suitable in other embodiments.
  • FIG. 63 shows a leaflet 6310 formed from a fabric according to the present disclosure including a wire 6320 extending from the attachment edge 6340 to the free edge 6350 of the leaflet.
  • Leaflet 6310 is illustrated with a partial or complete coating and/or layer positioned on the fabric.
  • Wire 6320 may be positioned through the fabric, the coating, or both. It may be adhered on top of the fabric layer as illustrated or laminated between the fabric layer and the coating layer.
  • FIG. 64 shows a leaflet 6410 formed from a fabric according to the present disclosure including a discontinuous wire 6420 extending from the attachment edge 6440 to the free edge 6450 of the leaflet.
  • Leaflet 6410 is illustrated with a partial or complete coating and/or layer positioned on the fabric.
  • Wire 6420 may be positioned through the fabric, the coating, through both, between the fabric and the coating or on one of the major surfaces.
  • FIG. 65 shows a leaflet 6510 formed from a fabric according to the present disclosure including a wire 6520 extending across a major surface of the leaflet and along the free edge 6550 of the leaflet, the wire being disposed between the fabric layer 6560 and a partial coating layer 6570.
  • FIG. 66 shows a leaflet 6610 formed from a fabric according to the present disclosure including a wire 6620 extending across a major surface of the leaflet and along the attachment edge 6640 of the leaflet.
  • the ends of the wire 6620 extend to the free edge 6660, although in other embodiments the ends of the wire may be spaced a distance from the free edge.
  • FIG. 67A illustrates the use of a wire 6720 adhered to a major surface of a fabric layer spaced apart from, but aligned roughly parallel to the free edge 6750 of leaflet 6710. Both of the free ends of this wire intersect the attachment edge 6740.
  • One such wire is shown but other rows of wire, continuous or discontinuous, may also be used. Instead of a wire, as illustrated, this could also be accomplished with a series of stitches, suture line(s), or an area of increased weave density.
  • FIG 67B several of these structures 6720ould also be placed roughly conforming to or paralleling the contour of the attachment edge 6740 spaced apart from each other. In this illustration, two such wires are disposed in a roughly concentric patters with their ends running between the fabric and a partial coating 6760 disposed at the free edge 6750 of leaflet 6710.
  • One coated fabric which may be useful for some applications is composed of five layers, two polymer layers (each about 20 pm thick) laminated to one side of a woven fabric and two other polymer layers (each about 20 pm thick) laminated to the other side of the same fabric.
  • These polymer layers may be, for example, made of Dyneema Purity ® membrane 55501 available from DSM Biomedical (www.dsmbiomedical.com).
  • Dyneema Purity ® membrane 55501 is composed of UHMWPE and is said to be known for uses in the medical device industry.
  • the properties of Dyneema Purity ® membrane 55501 are specified in its Product Data Sheet from DSM Biomedical dated June 2015.
  • Dyneema Purity ® TG dtexlO TS450 may be an example of a suitable fiber for use in producing the fabrics disclosed herein, including for cuffs and/or leaflets of a prosthetic heart valve.
  • the properties of Dyneema Purity ® TG dtexlO TS450 are specified in its Product Data Sheet from DSM Biomedical dated September 2013. That fabric may be used in uncoated form, or may include Dyneema Purity ® membrane 55501 as one or more polymer coating layers.
  • the desired fabric material After the desired fabric material has been created and shaped or cut, it will typically need to be connected to a supporting structure (such as a stent if the material is intended for use as a cuff and/or prosthetic leaflets).
  • the attachment may be accomplished through any one of a number of suitable methods, including suturing, heat bonding, weaving or knitting directly to the supporting structure, gluing, wrapping, electrospinning, laminating, mechanical attachment such as hooks, hook-and-loop fasteners, being sandwiched between two supporting structures, or being bonded directly to the supporting structure, such as integrating the fabric to the supporting structure while the supporting structure is in a non-set state (e.g., a liquid) in which curing the supporting structure results in the fabric being integrated into the supporting structure.
  • a non-set state e.g., a liquid
  • the fabric In attaching fabric-based components to a stent and/or to another support structure of a medical device, the fabric may be attached such that the frbers are oriented in a particular direction. This consideration applies both to uncoated fabrics, as well as coated fabrics described below. Most woven fabrics are produced using fibers that are woven at right angles to each other. These fabrics may be cut and attached to the support structure such that the direction of at least one of the fibers in the weave is substantially parallel to the longitudinal axis of the support structure, and another fiber is oriented generally perpendicular to the longitudinal axis of the support structure. Alternatively, these fabrics may be mounted to the support structure such that the fibers are generally oriented on a bias, i.e.
  • the fabrics may, for example, be used to form an inner cuff and/or an outer cuff of a cohapsible/expandable heart valve or the skirt or other fabric covering of a surgical heart valve.
  • the oblique angle may be between about 30 degrees and about 60 degrees relative to the longitudinal axis of the support structure when the heart valve is in an expanded use condition.
  • the fabric may be oriented such that the fibers are oriented at about 45 degrees relative to the longitudinal axis of the support structure when the heart valve is in an expanded use condition.
  • One aspect of the disclosure is a cohapsible/expandable heart valve which may be implanted through a catheter or trocar, the heart valve including a valve assembly comprising a coated or uncoated fabric as described herein, and in particular, a heart valve in which the coated or uncoated fabric is used to form the leaflets and/or cuffs shown in FIGS. 28-46A.
  • the outer cuff may be made of a coated or uncoated fabric of the disclosure.
  • the inner cuff may be made of a coated or uncoated fabric of the disclosure.
  • both the inner and outer cuffs may be made of a coated or uncoated fabric of the disclosure.
  • the inner cuff may be coated while the outer cuff is not.
  • the inner cuff may be uncoated and the outer cuff may be coated.
  • At least one leaflet may be made from a coated or uncoated fabric material in accordance with the disclosure.
  • some, but not all of the leaflets may be made from a coated or uncoated fabric material in accordance with the disclosure. It is also contemplated that all leaflets may be produced from a coated or uncoated fabric material in accordance with the disclosure. In one desirable embodiment, all of the leaflets may be made of the same uncoated fabric of the disclosure. In another embodiment, all of the leaflets may be made of the same coated fabric of the disclosure.
  • At least one cuff and at least one leaflet of the valve assembly may be composed of a coated or uncoated fabric of the disclosure.
  • both the at least one cuff and the at least one leaflet of the valve assembly may be made of a coated fabric in accordance with the disclosure.
  • both the cuff and the leaflet may be made from an uncoated fabric in accordance with the present disclosure.
  • Prosthetic venous valves may have generally similar structures and components as those described for the prosthetic heart valves, including a stent, one or more prosthetic leaflets, and optionally inner and/or outer cuffs. If the stent is self-expandable or balloon expandable, the stent may maintain a desired position within the vasculature via a friction fit.
  • the stent may be sutured or otherwise fixed at the desired position within the vasculature.
  • the one or more prosthetic leaflets may be coupled to the stent and/or to an inner and/or outer cuff attached to the stent, for example via sutures.
  • the prosthetic leaflets may allow blood to flow in substantially only one direction within the vasculature.
  • the inner and/or outer cuffs may assist in enhancing sealing to help prevent blood from flowing in the retrograde direction past the prosthesis, and may also aid in coupling the one or more prosthetic leaflets to the stent.
  • the prosthetic leaflets, inner cuffs, and outer cuffs of the prosthetic venous valves may be formed of any of the materials described above for similar components of the prosthetic cardiac valves, for example including the uncoated and/or coated fabrics described herein.
  • the uncoated and/or coated fabrics described herein may have still further applications, for example with occluders, which may also be referred to as closure devices.
  • occluders may be used to treat any suitable abnormality or condition, including patent foramen ovale (“PFO”), atrial septal defect (“ASD”), ventricular septal defect (“VSD”), patent ductus arteriosus (“PDA”), and left atrial appendage (“LAA”) closure.
  • Occluders may have various different configurations depending on factors such as the type of abnormality to be occluded, the location of the target site, the condition of the patient’s vasculature or cardiac anatomy, and the practitioner’s preferences.
  • the occluders described herein have a collapsed condition and an expanded condition.
  • a closure device 2000 has a first expanded volume portion 2010 and a second expanded volume portion 2020 that are substantially perpendicular to a central axis extending along closure device 2000.
  • the first expanded volume portion 2010 may be proximate a first end of closure device 2000, with the second expanded volume portion 2020 spaced axially from the first expanded volume portion 2010 and proximate a second end of closure device 2000.
  • the first expanded volume portion 2010 may be connected to the second expanded volume portion 2020 via an axial portion 2030.
  • the first expanded volume portion 2010 in the expanded condition may have the shape of a thin disk, and is intended to help maintain the closure device 2000 in position at the target site, as described in greater detail below.
  • the second expanded volume portion 2020 in the expanded condition may, in some cases, be a generally cylindrical body that is substantially thicker in the axial direction than the first expanded volume portion 2010 and axially disposed toward the second end.
  • the second expanded volume portion 2020 when expanded may be sized to be somewhat larger in diameter (e.g., about 10-30% larger) than the inside diameter of the vessel, cavity, or lumen to be occluded to facilitate anchoring of the device to prevent dislodgement, but not so large when collapsed as to not fit in the vessel, cavity or lumen.
  • the first expanded volume portion 2010 of the closure device 2000 may have a diameter that is larger than the diameter of the second expanded volume portion 2020. This larger diameter is intended to abut the wall surrounding the abnormal aperture to prevent device movement further into the aperture and to assist in sealing the aperture.
  • the first expanded volume portion 2010 may be oversized so as to overlie the ostium or opening of the LAA in a position adjacent to, and in flush contact with, the wall of the atrium.
  • the first expanded volume portion 2010 may also be flexible so as to be capable of conforming to the curvature of the wall of the atrium in LAA applications or other cardiac or vascular structures in other applications.
  • first and second expanded volume portions 2010, 2020 are described above and shown in the figures, various other configurations and sizes may be used depending on the particular application or condition to be treated.
  • one or both expanded volume portions 2010, 2020 may be thin disks or disks having a convex distal end, or the device may include a smaller diameter cylindrical portion between two larger diameter disks.
  • the depth or thickness of the first and/or second expanded volume portions may depend on the thickness and number of layers used to make the closure device 2000.
  • the first expanded volume portion 2010, the second expanded volume portion 2020, and the axial portion 2030 may each be formed of a shape-memory alloy, such as braided nitinol, to facilitate collapsing the closure device 2000 for minimally invasive delivery, and to facilitate expansion to a pre-set shape upon delivery of the closure device 2000 to the intended location.
  • a first coupling 2015 may be disposed adjacent the first expanded volume portion 2010 and may enable connection of a delivery device or other device to closure device 2000.
  • first coupling 2015 may include internal or external threads that mate with corresponding threads of another device.
  • a second coupling 2025 similar to the first coupling 2015, may be disposed adjacent to or within the second expanded volume portion 2020.
  • Second coupling 2025 may also include internal or external threads for connection to corresponding threads of another device. It should be understood that other coupling mechanisms, such as press-fit or snap-fit arrangements, may be utilized in first and second couplings 2015, 2025. Additional details of closure device 2000 and similar devices are described in U.S. Patent No. 8,758,389, the disclosure of which is hereby incorporated by reference herein.
  • FIG. 27B is a schematic view of closure device 2000 positioned within the LAA of a left atrium LA.
  • a device such as closure device 2000 may lead to partial or complete occlusion of the LAA, thus reducing the risk of thrombi breaking off the LAA and entering the blood stream.
  • it may be desirable to include fabrics on the interior surface, exterior surface, or both surfaces of the closure device 2000.
  • part or all of the outer surface, and/or part or all of the inner surface, of closure device 2000 may include one or more layers of the uncoated and/or coated fabrics described herein.
  • closure device 2000 may help better and/or more quickly occlude the LAA.
  • portions of closure device 2000 are formed of two or more layers of braided metal, such as braided nitinol, uncoated and/or coated fabrics of the present disclosure may be included between the two or more layers of braided metal.
  • Other closure devices such as PFO closure devices, may similarly include uncoated and/or coated fabrics of the present disclosure on part or all of an exterior surface and/or on part or all of an interior surface (and/or between multiple layers of braided mesh if present), for similar purposes as described in connection with closure device 2000.
  • the uncoated and/or coated fabrics described herein may also be used to form the entirety, or portions, of various types of prosthetic vascular conduits.
  • a prosthetic aortic graft may be implanted into the aorta to treat a weakened portion of the aorta resulting from a thoracic aneurysm.
  • Prosthetic vascular conduits may be used to perform a bypass to reroute the path of blood flow, for example as a lower extremity bypass, a cardiac bypass in conjunction with open heart surgery, or to serve as an access point to the circulatory system, such as for hemodialysis.
  • Prosthetic vascular conduits may also be used as arteriovenous (“AV”) shunts.
  • AV arteriovenous
  • AV fistulas are abnormal connections between an artery and vein, although they may be surgically created in order to assist with hemodialysis treatment.
  • an AV shunt formed from the uncoated and/or coated fabrics described herein may be implanted to provide the desired connection between the artery and vein.
  • Prosthetic vascular conduits are typically cylindrical in shape and have been formed of PTFE or Dacron. However, prosthetic vascular grafts may instead be formed of the uncoated and/or coated fabrics described herein.
  • the fabrics described herein may have additional uses.
  • hernias occur when there is an opening or a weakness in the muscle and/or connective tissue through which organs begin to push.
  • Hernias are frequently treated with a fabric mesh that provides closure and support of the weakness and/or opening that forms the hernia.
  • the mesh acts to patch the hernia, and is frequently formed of a plastic material.
  • patches may instead be formed of the uncoated or coated fabrics disclosed herein, whether the patches are continuous or formed as a mesh.
  • hernia repair is one exemplary use of patches formed of the uncoated or coated fabrics disclosed herein, such patches may be used in any other suitable procedure, including skin patches, vaginal patches, and/or cardiac patches to provide the desired support to the underlying anatomy.
  • the fabrics described herein may be used to form adhesion barriers.
  • Adhesion barriers are medical implants that may be used to reduce abnormal internal scarring following surgery.
  • the uncoated or coated fabrics of the adhesion barriers may act to separate internal tissues and/or organs while they heal post-surgery.
  • an embolic protection device may be used to prevent emboli that are dislodged during a medical procedure from entering the vasculature.
  • embolic protection devices either capture dislodged emboli so that the emboli can be removed from the body, or otherwise deflect emboli from entering high-risk vasculature (such as the carotid arteries) so that the emboli are able to pass through the vasculature where there may be a lower risk of complications from the emboli.
  • Embolic protection devices may include various types of filters that allow blood to pass through the filter, but are formed as meshes or with pore sizes small enough to trap emboli therein, or otherwise to deflect emboli. Such embolic protection devices may be formed of the fabrics described herein. Examples of embolic protection devices are disclosed in greater detail in U.S. Patent Pub. Nos.
  • IVC filters typically have a central base and a plurality of legs that extend outwardly from the base to form an overall conical shape, with the legs intended to make contact with the interior surface of the lumen of the IVC to help support the IVC filter in place.
  • the IVC filter functions by allowing blood to flow around the filter, while trapping emboli that pass into the filter, preventing the emboli from causing blockages in the vasculature downstream of the IVC filter.
  • the IVC filters may be formed of a metal or other biocompatible material and the uncoated and coated fabrics described herein may encapsulate portions or all of the IVC filter, or in other embodiments the IVC filter may be formed entirely of the coated fabrics described herein. It should be understood that for IVC filters, or any other application disclosed herein, specific parameters of the disclosed fabrics, such as dimensions, as well as fabrication methods, may be altered to suit the particular application.
  • collapsible and expandable prosthetic heart valves have been described above which may incorporate the fabrics described herein.
  • the prosthetic collapsible and expandable heart valves have generally been described in connection with a prosthetic aortic valve, those heart valves may be designed for replacing any heart valve.
  • collapsible and expandable prosthetic mitral valves may include an outer stent portion to anchor into the mitral valve annulus, and an inner stent portion to house the prosthetic leaflets, with the inner stent connected to the outer stent, for example so that the inner stent is substantially mechanically isolated from the outer stent.
  • the outer stent portion may include features to help secure the prosthetic mitral valve within the mitral valve annulus
  • the inner stent portion may be substantially cylindrical (e.g. a right cylinder) so that the valve assembly may have a generally circular profile in cross section.
  • the fabrics described herein may be used for prosthetic leaflets of the prosthetic mitral valve and/or for any cuffs or skirts on the prosthetic mitral valve, which may include inner cuffs and/or outer cuffs of the inner stent portion and the outer stent portion, as well as any other cuff or skirt portions, such as cuff portions that connect the inner stent portion to the outer stent portion.
  • Prosthetic mitral valves having inner and outer stent portions are described in greater detail, for example, in U.S. Patent Publication Nos. 2017/0196688 and 2019/0328525, and U.S. Patent No. 10,052,204, the disclosures of which are hereby incorporated by reference herein.
  • a prosthetic heart valve comprises: an expandable stent extending in a longitudinal direction between an inflow end and an outflow end; a cuff coupled to a luminal surface of the stent; and a plurality of prosthetic leaflets coupled to at least one of the cuff and the stent and having an open condition and a closed condition, the plurality of prosthetic leaflets adapted to allow blood to flow from the inflow end toward the outflow end when in the open condition and to retard blood from flowing from the outflow end toward the inflow end when in the closed condition, each of the plurality of leaflets being formed of a fabric; wherein the fabric has a first group of fibers extending in a first direction of the fabric and a second group of fibers extending in a second direction of the fabric different than the first direction, the first group of fibers and the second group of fibers being interlaced in an ordered arrangement, the first group of fibers and the second group of fibers both being composed of ultra-high mole
  • a prosthetic heart valve comprises: an expandable stent having a luminal surface; and a valve assembly attached to the luminal surface of the stent, the valve assembly including a cuff and a leaflet, the leaflet having a first major surface, an opposed second major surface, an attachment edge, a free edge, and a plurality of tabs, both the cuff and the leaflet composed of an uncoated woven fabric composed of a polymer, the woven fabric having a thread count of 300-500 x 100-300 fibers per square inch, an areal density of between 0.5 and 1.0 ounces/yd 2 , a thickness of between about 20 and about 250 pm, and a tensile strength of between about 50 N and about 100 N; and/or the polymer is polytetrafluoroethylene (“PTFE”); and/or the polymer is low density PTFE, high density PTFE, or ultra-high molecular weight PTFE (“UHMWPTFE”
  • a prosthetic heart valve comprises: an expandable stent having a luminal surface; and a valve assembly attached to the luminal surface of the stent, the valve assembly including a cuff and a leaflet, the leaflet having a first major surface, an opposed second major surface, an attachment edge, a free edge, and a plurality of tabs, both the cuff and the leaflet composed of a woven fabric composed of a first polymer, the leaflet further comprising a coating composed of a second polymer disposed on at least one of the first major surface and the second major surface; and/or the woven fabric has an areal density of between 0.5 and 1.0 ounces/yd 2 ; and/or the woven fabric has an areal density of about 0.5 ounces/yd 2 ; and/or the woven fabric has an areal density of about 0.8 ounces/yd 2 ; and/or the woven fabric has an areal density of about 1.0 ounces
  • a prosthetic heart valve comprises: an expandable stent having a luminal surface; and a valve assembly attached to the luminal surface of the stent, the valve assembly including a cuff and a leaflet, the leaflet having a first major surface, an opposed second major surface, an attachment edge, a free edge, and a plurality of tabs, both the cuff and the leaflet composed of a woven fabric composed of a first polymer, at least one of the attachment edge, the free edge, and the plurality of tabs the leaflet further comprising a coating composed of a second polymer disposed on at least one of the attachment edge, the free edge, and the plurality of tabs; and/or the woven fabric has an areal density of between 0.5 and 1.0 ounces/yd 2 ; and/or the woven fabric has an areal density of about 0.5 ounces/yd 2 ; and/or the woven fabric has an areal density of about 0.8 ounces/y
  • a prosthetic heart valve comprises: an expandable stent having a luminal surface and an abluminal surface; a cuff disposed on the abluminal surface of the stent; and at least two prosthetic leaflets each having a first major surface, an opposed second major surface, an attachment edge, a free edge, and a plurality of tabs, both the cuff and the at least two prosthetic leaflets being composed of a woven fabric composed of a polymer, the woven fabric having a thread count of 300- 500 x 100-300 fibers per square inch, an areal density of between 0.5 and 1.0 ounces/yd 2 , a thickness of between about 20 and about 250 pm, and a tensile strength of between about 50 N and about 100 N; and/or the polymer is polytetrafluoroethylene (“PTFE”); and/or the polymer is low density PTFE, high density PTFE, or ultra-high molecular weight PTFE (“UH
  • an uncoated woven fabric leaflet for a prosthetic replacement heart valve comprises: a piece of woven polymer fabric comprising a first major surface, a second major surface, an attachment edge and a free edge, said polymer fabric composed of polyethylene (“PE”), polypropylene (“PP”) or polytetrafluoroethylene (“PTFE”) fibers and having a thread count of 300-500 x 100-300 fibers per square inch, a thickness of between about 10 pm and about 200 pm, and an areal density of no more than about 1.0 ounces/yard 2 ; and/or indicia composed of a radiopaque fiber forming a portion of the woven polymer fabric; and/or at least one grommet in the woven polymer fabric adjacent the attachment edge; and/or a plurality of tabs disposed on the woven polymer fabric adapted to form of commissures; and/or at least one grommet is disposed in each of the plurality of tabs; and
  • PE polyethylene
  • PP polypropylene
  • a coated woven fabric leaflet for a prosthetic replacement heart valve comprises: a piece of woven polymer fabric comprising a first major surface and an opposed second major surface, an attachment edge and a free edge, said polymer fabric composed of polyethylene (“PE”), polypropylene (“PP”) or polytetrafluoroethylene (“PTFE”) fibers and having a thread count of 300-500 x 100-300 fibers per square inch, a thickness of between about 10 pm and about 200 pm, and an areal density of no more than about 1.0 ounces/yard 2 ; and a coating disposed on at least one of the first major surface and the second major surface, the coating composed of PE, PP or PTFE, wherein the piece of woven polymer fabric, including the coating, has a thickness no greater than about 250 pm; and/or indicia composed of a radiopaque fiber forming a portion of the woven fabric; and/or at least one grommet in the woven polymer fabric adjacent the
  • a valve assembly comprises: a cuff; and three prosthetic leaflets sutured or laced to the cuff, each leaflet composed of an uncoated piece of woven polymer fabric having a first major surface, a second major surface, an attachment edge, a free edge, and a plurality of tabs, wherein the polymer fabric is composed of polyethylene (“PE”), polypropylene (“PP”) or polytetrafluoroethylene (“PTFE”) fibers and has a thread count of 300-500 x 100-300 fibers per square inch, a thickness of between about 10 pm and 200 pm, and an areal density of no more than about 1.0 ounces/yard 2 ; and/or three commissures formed by tabs of adjacent ones of the three leaflets being sutured or laced together.
  • PE polyethylene
  • PP polypropylene
  • PTFE polytetrafluoroethylene
  • a prosthetic valve assembly comprises: a cuff; and three prosthetic leaflets sutured or laced to the cuff, each leaflet composed of an uncoated piece of woven polymer fabric having a first major surface, a second major surface, an attachment edge, a free edge and a plurality of tabs, the polymer fabric being composed of polyethylene (“PE”) or polytetrafluoroethylene (“PTFE”) fibers and having a thread count of 300-500 x 100-300 fibers per square inch, a thickness of between about 50 pm and 100 pm, and an areal density of more than about 0.65 ounces/yard 2 ; and a coating disposed on at least one of the first major surface and the second major surface, the coating being composed of PE or PTFE, woven polymer fabric and the coating together having a thickness no greater than about 250 pm; and/or three commissures formed by tabs of adjacent ones of the three prosthetic leaflets being sutured or laced together; and/
  • an uncoated knitted fabric leaflet for a prosthetic heart valve comprises: a piece of knitted polymer fabric comprising a first major surface, a second major surface, an attachment edge and a free edge, the polymer fabric composed of polyethylene (“PE”), polypropylene (“PP”), or polytetrafluoroethylene (“PTFE”) fibers and having a stitch density of between about 2 and about 750 loops per square inch (Wales density x courses per inch) and a thickness of between about 10 pm and about 200 pm.
  • PE polyethylene
  • PP polypropylene
  • PTFE polytetrafluoroethylene
  • a coated knitted fabric leaflet for a prosthetic heart valve comprises: a piece of knitted polymer fabric comprising a major surface and an opposed major surface, an attachment edge and a free edge, the polymer fabric composed of polyethylene (“PE”), polypropylene (“PP”), or polytetrafluoroethylene (“PTFE”) fibers and having a stitch density of between about 2 and about 750 loops per square inch and a thickness of between about 10 pm to 200 pm; and at least one coating disposed on at least one of the major surface and the opposed major surface, the at least one coating composed of PE, PP or PTFE, wherein the at least one coating has a total thickness of between about 2 pm and about 50 pm, such that the coated knitted fabric has a total thickness no greater than about 250 pm.
  • PE polyethylene
  • PP polypropylene
  • PTFE polytetrafluoroethylene
  • a prosthetic valve assembly comprises: a cuff; and three prosthetic leaflets sutured or laced to the cuff, at least one of the cuff and the prosthetic leaflets composed of an uncoated piece of knitted polymer fabric comprising a first major surface, a second major surface, an attachment edge, a free edge and a plurality of tabs, the polymer fabric being composed of polyethylene (“PE”), polypropylene (“PP”), or polytetrafluoroethylene (“PTFE”) fibers and having a stitch density of between about 2 and about 750 loops per square inch, and a thickness of between about 10 pm and about 200 pm.
  • PE polyethylene
  • PP polypropylene
  • PTFE polytetrafluoroethylene
  • a prosthetic valve assembly comprises: a cuff; and three prosthetic leaflets sutured or laced to the cuff, at least one of the cuff and the leaflets composed of a coated piece of knitted polymer fabric comprising a first major surface, a second major surface, an attachment edge, a free edge and a plurality of tabs, the polymer fabric composed of polyethylene (“PE”), polypropylene (“PP”), or polytetrafluoroethylene (“PTFE”) fibers and having a stitch density of between about 2 and about 750 loops per square inch, a thickness of between about 10 pm and about 200 pm, and at least once coating composed of PE, PP or PTFE, the at least one coating having a total thickness of between about 2 pm and about 50 pm.
  • PE polyethylene
  • PP polypropylene
  • PTFE polytetrafluoroethylene
  • a process for assembling a medical device comprises: lacing a fiber through a grommet provided in a first coated or uncoated woven or knitted polymer fabric; and attaching the first coated or uncoated woven or knitted polymer fabric to a stent, superstructure, support or a second coated or uncoated woven or knitted polymer fabric using the fiber; and/or the first coated or uncoated woven or knitted polymer fabric is attached to the second coated or uncoated woven or knitted polymer fabric; and/or the first coated or uncoated woven or knitted polymer fabric is also attached to the stent.
  • a prosthetic heart valve comprises: an expandable stent; a prosthetic leaflet having a first major surface and a second opposed major surface; and a cuff having a first major surface and a second opposed major surface, the prosthetic leaflet being attached to both the stent and the cuff, the prosthetic leaflet and the cuff both being composed of a woven polymer fabric, at least a portion of one of the first major surfaces and the second opposed major surfaces of the leaflet or the cuff being coated with at least one layer of a bio-absorbable or biodegradable polymer coating; and/or the at least one layer of the bio-absorbable or biodegradable polymer coating is selected from the group consisting of: poly-glycolic acid, poly-L- lactic acid, copolymers of poly-glycolic acid, poly-L- lactic acid, polycaprolactone, poly-DL lactic acid, polytrimethylene carbonate, polydiox
  • a cuff and/or prosthetic leaflet for a replacement heart valve, where the cuff and/or prosthetic leaflet is composed of a coated or uncoated woven polymer fabric.
  • the woven polymer fabric has at least one of the following properties: an ultimate tensile strength of from about 1 to about 500 MPa; a tear strength of from about 5 to aboutlOO lbF; a permeability of from about 1 to about 2,000 mL/cm 2 /min if coated to reduce permeability; a suture retention of from about 10 to about 100 N; a stiffness/flexural rigidity of from about 0.001 to about 8 cm; and a stretch of from about 1 to about 400%.
  • the prosthetic leaflet has a thickness of from about 5 pm to about 500 pm and the cuff has a thickness of from about 1 pm to about 300 pm.
  • Another aspect of this embodiment is a valve assembly made with this cuff and/or prosthetic leaflet and in still another aspect there is provided a surgical or expandable replacement heart valve including this valve assembly.
  • the cuff and/or prosthetic leaflet is composed of a coated or uncoated woven polymer fabric material having at least one of the following properties: an ultimate tensile strength of from 25-250 MPa; a tear strength of 10-40 lbF; a permeability of 10-1,200 mL/cm 2 /min if coated to reduce permeability; a suture retention of 30-70 N; a stiffness/flexural rigidity of 0.001-4 cm; and a stretch of 3-50%.
  • the prosthetic leaflet has a thickness of from about 50 pm to about 350 pm and the cuff has a thickness of from about 5 pm to about 200 pm.
  • Another aspect of this embodiment is a valve assembly made with this cuff and/or prosthetic leaflet and in still another aspect there is provided a surgical or expandable replacement heart valve including this valve assembly.
  • a replacement heart valve comprises: a self-expandable or balloon-expandable stent, and a valve assembly sutured to the stent.
  • the valve assembly comprises at least one cuff attached to a luminal and/or an abluminal surface of the stent and two or three prosthetic leaflets attached to the cuff and/or the luminal surface of the stent.
  • the cuff(s) and prosthetic leaflets are composed of a coated or uncoated woven polymer fabric composed of one or more woven fabric layers of ultra-high molecular weight polyethylene or polytetrafluoroethylene which exhibit at least one of the following properties: an ultimate tensile strength of from about 25 to about 250 MPa; a tear strength of from about 10 to about40 lbF; a permeability of from about 10 to about 1,200 mL/cm 2 /min if coated to reduce permeability; a suture retention of from about 30 to about 70 N; a stiffness/flexural rigidity of from about 0.001 to about 4 cm or a stretch of from about 3 to about 50%.
  • the prosthetic leaflets have a thickness of from about 50 pm to about 350 pm and the cuff has a thickness of from about 5 pm to about 200 pm.
  • one of the prosthetic leaflets and/or the cuffs comprises at least one woven polymer fabric layer and attached thereto a second layer that provides at least one of the following advantages when compared to the cuff or leaflet without that layer: (i) adjusts surface roughness; (ii) alters leaflet strength; (iii) provides added abrasion resistance; (iv) provides improved lubricity; (v) adds weight to bias the leaflet to close; (vi) provides additional rigidity; (vii) promotes folding; (viii) alters cell adhesion; (ix) controls cellular ingrowth; (x) improves resistance to thrombosis; or (xi) includes a therapeutic agent.
  • a replacement heart valve comprises: a self- expandable or balloon-expandable stent, and a valve assembly sutured to the stent.
  • the valve assembly comprises a cuff attached to a luminal and/or an abluminal surface of the stent, and a plurality of prosthetic leaflets attached to the cuff and/or the luminal surface of the stent.
  • the cuff and prosthetic leaflets are composed of a coated or uncoated woven polymer fabric itself composed of one or more layers of ultra- high molecular weight polyethylene or polytetrafluoroethylene.
  • At least one layer of the woven polymer fabric or their combination exhibits one of the following properties: an ultimate tensile strength of from about 25 to about 250 MPa; a tear strength of from about 10 to about 40 lbF; a permeability of from about 10 to about 1,200 mL/cm 2 /min; a suture retention of from about 30 to about 70 N; a stiffness/flexural rigidity of from about 0.001 to about 4 cm; or a stretch of from about 3 to about 50%.
  • the prosthetic leaflets have a thickness of from about 50 pm to about 350 pm and the cuff has a thickness of from about 5 pm to about 200 pm.
  • One or more of the prosthetic leaflets or the cuff further comprises a wire, stitch, a suture line or grommet.
  • a stitch or a suture line they are not provided to substantially attach the cuff or leaflet to another structure of the replacement heart valve.
  • the prosthetic mitral valve comprises a self-expandable or balloon-expandable stent that includes a first inner stent portion having a generally cylindrical shape and a second outer stent portion attached to the first inner stent portion.
  • the second outer stent portion is disposed generally surrounding the first inner stent portion.
  • the second outer stent portion When implanted into a native mitral valve annulus, the second outer stent portion engages the native valve annulus and at least partially mechanically isolates the first inner stent portion from being deformed by the anatomy of the native valve annulus or calcification of the native valve. Thus, the first inner stent portion retains its generally cylindrical shape.
  • the prosthetic mitral valve includes a valve assembly that is substantially only attached to the first inner stent portion.
  • the valve assembly comprises at least one cuff attached to a surface of the stent and two or three prosthetic leaflets attached to the cuff and/or the luminal surface of the first inner stent portion.
  • the cuff(s) and/or prosthetic leaflets are composed of a coated or uncoated woven polymer fabric itself composed of one or more layers of ultra-high molecular weight polyethylene or polytetrafluoroethylene. At least one layer of the woven polymer fabric exhibits one of the following properties: an ultimate tensile strength of from about 25 to about 250 MPa; a tear strength of from about 10 to about 40 lbF; a permeability of from about 10 to about 1,200 mL/cm2/min; a suture retention of from about 30 to about 70 N; a stiffness/flexural rigidity of from about 0.001 to about 4 cm; or a stretch of from about 3 to about 50%.
  • the prosthetic leaflets have a thickness of from about 50 pm to about 350 pm and the cuff has a thickness of from about 5 pm to about 200 pm.
  • the at least one of the prosthetic leaflets or the cuff further comprises a wire, stitch, a suture line or grommet. In the case of a stitch or a suture line, they are not provided to substantially attach the cuff or prosthetic leaflet to another structure of the replacement heart valve.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Manufacturing & Machinery (AREA)
  • Materials Engineering (AREA)
  • Prostheses (AREA)

Abstract

Au moins une partie de textiles (404) à utiliser dans des dispositifs médicaux (10, 100, 2000) est formée à partir de matériaux polymères. Les textiles peuvent être non revêtus, partiellement revêtus ou entièrement revêtus d'une ou plusieurs couches (402) d'un polymère. Les textiles peuvent être utilisés pour les valves (108) et/ou les ballonnets (106) de valves cardiaques prothétiques (100) et comme composant d'autres dispositifs médicaux (2000).
EP20753484.3A 2020-06-11 2020-06-11 Matériau textile pour dispositifs médicaux Pending EP4164551A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2020/037274 WO2021251974A1 (fr) 2020-06-11 2020-06-11 Matériau textile pour dispositifs médicaux

Publications (1)

Publication Number Publication Date
EP4164551A1 true EP4164551A1 (fr) 2023-04-19

Family

ID=71995025

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20753484.3A Pending EP4164551A1 (fr) 2020-06-11 2020-06-11 Matériau textile pour dispositifs médicaux

Country Status (2)

Country Link
EP (1) EP4164551A1 (fr)
WO (1) WO2021251974A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116251238B (zh) * 2023-02-28 2023-11-21 上海心纪元医疗科技有限公司 具有三层结构的仿生瓣膜瓣叶及其制造方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2852811A (en) 1954-03-01 1958-09-23 John V Petriello Method for casting thin plastic films
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4056854A (en) 1976-09-28 1977-11-08 The United States Of America As Represented By The Department Of Health, Education And Welfare Aortic heart valve catheter
US4610688A (en) 1983-04-04 1986-09-09 Pfizer Hospital Products Group, Inc. Triaxially-braided fabric prosthesis
US4610918A (en) 1984-04-13 1986-09-09 Chemical Fabrics Corporation Novel wear resistant fluoropolymer-containing flexible composites
US5411552A (en) 1990-05-18 1995-05-02 Andersen; Henning R. Valve prothesis for implantation in the body and a catheter for implanting such valve prothesis
US5370685A (en) 1991-07-16 1994-12-06 Stanford Surgical Technologies, Inc. Endovascular aortic valve replacement
US5624461A (en) 1995-06-06 1997-04-29 Target Therapeutics, Inc. Three dimensional in-filling vaso-occlusive coils
US5855601A (en) 1996-06-21 1999-01-05 The Trustees Of Columbia University In The City Of New York Artificial heart valve and method and device for implanting the same
EP0850607A1 (fr) 1996-12-31 1998-07-01 Cordis Corporation Prothèse de valve pour implantation dans des canaux corporels
US5957949A (en) 1997-05-01 1999-09-28 World Medical Manufacturing Corp. Percutaneous placement valve stent
US6458153B1 (en) 1999-12-31 2002-10-01 Abps Venture One, Ltd. Endoluminal cardiac and venous valve prostheses and methods of manufacture and delivery thereof
US6821297B2 (en) 2000-02-02 2004-11-23 Robert V. Snyders Artificial heart valve, implantation instrument and method therefor
WO2001056512A1 (fr) 2000-02-02 2001-08-09 Snyders Robert V Valvule cardiaque artificielle
WO2002024119A1 (fr) * 2000-09-21 2002-03-28 St. Jude Medical, Inc. Protheses a valves comportant des valves polymeres renforcees
FR2828091B1 (fr) 2001-07-31 2003-11-21 Seguin Jacques Ensemble permettant la mise en place d'une valve prothetique dans un conduit corporel
US6893460B2 (en) 2001-10-11 2005-05-17 Percutaneous Valve Technologies Inc. Implantable prosthetic valve
US7109135B2 (en) 2002-12-03 2006-09-19 Central Products Company Soft tactile coating for multi-filament woven fabric
US7780725B2 (en) 2004-06-16 2010-08-24 Sadra Medical, Inc. Everting heart valve
DK2926766T3 (en) 2003-12-23 2016-05-17 Boston Scient Scimed Inc REPONIBLE HEART VALVE
DE202008018551U1 (de) 2007-08-21 2015-10-26 Symetis Sa Eine Ersatzklappe
US8425593B2 (en) 2007-09-26 2013-04-23 St. Jude Medical, Inc. Collapsible prosthetic heart valves
EP3141219A1 (fr) 2008-04-23 2017-03-15 Medtronic, Inc. Dispositifs de valvule cardiaque à stent
EP4176845A1 (fr) 2008-07-15 2023-05-10 St. Jude Medical, LLC Conceptions de manchon de valvule cardiaque prothétique repliable et redéployable
AU2011293898B2 (en) 2010-08-24 2014-09-18 St. Jude Medical, Inc. Staged deployment devices and methods for transcatheter heart valve delivery systems
US9039757B2 (en) 2011-10-19 2015-05-26 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US8758389B2 (en) 2011-11-18 2014-06-24 Aga Medical Corporation Devices and methods for occluding abnormal openings in a patient's vasculature
US9827092B2 (en) 2011-12-16 2017-11-28 Tendyne Holdings, Inc. Tethers for prosthetic mitral valve
ES2690824T3 (es) 2012-07-02 2018-11-22 Boston Scientific Scimed, Inc. Formación de prótesis valvular cardiaca
US9295549B2 (en) 2012-10-12 2016-03-29 St. Jude Medical, Cardiology Division, Inc. Valve holder and loading integration
US9888993B2 (en) 2013-03-01 2018-02-13 St. Jude Medical, Cardiology Division, Inc. Embolic protection device
US10973618B2 (en) 2013-03-01 2021-04-13 St. Jude Medical, Cardiology Division, Inc. Embolic protection device
US10271949B2 (en) 2013-03-12 2019-04-30 St. Jude Medical, Cardiology Division, Inc. Paravalvular leak occlusion device for self-expanding heart valves
US9326856B2 (en) 2013-03-14 2016-05-03 St. Jude Medical, Cardiology Division, Inc. Cuff configurations for prosthetic heart valve
US9610159B2 (en) 2013-05-30 2017-04-04 Tendyne Holdings, Inc. Structural members for prosthetic mitral valves
US10583003B2 (en) * 2014-05-06 2020-03-10 Dsm Ip Assets B.V. Method of making a prosthetic valve and valve obtained therewith
WO2015169866A1 (fr) 2014-05-06 2015-11-12 Dsm Ip Assets B.V. Valvule prothétique et procédé de fabrication de valvule prothétique
US10195025B2 (en) 2014-05-12 2019-02-05 Edwards Lifesciences Corporation Prosthetic heart valve
WO2015175524A1 (fr) * 2014-05-16 2015-11-19 St. Jude Medical, Cardiology Division, Inc. Étanchéité annulaire secondaire pour protection contre des fuites paravalvulaires
US10299915B2 (en) 2015-04-09 2019-05-28 Boston Scientific Scimed, Inc. Synthetic heart valves composed of zwitterionic polymers
US10667904B2 (en) 2016-03-08 2020-06-02 Edwards Lifesciences Corporation Valve implant with integrated sensor and transmitter
EP3454785B1 (fr) * 2016-05-13 2021-11-17 St. Jude Medical, Cardiology Division, Inc. Valvule cardiaque à stent ayant des densités cellulaires variables
US10548722B2 (en) 2016-08-26 2020-02-04 St. Jude Medical, Cardiology Division, Inc. Prosthetic heart valve with paravalvular leak mitigation features
CR20190381A (es) 2017-01-23 2019-09-27 Cephea Valve Tech Inc Valvulas mitrales de reemplazo
CA3120097C (fr) * 2018-12-13 2023-07-04 Abbott Laboratories Materiau textile pour dispositifs medicaux

Also Published As

Publication number Publication date
WO2021251974A1 (fr) 2021-12-16

Similar Documents

Publication Publication Date Title
CA3120097C (fr) Materiau textile pour dispositifs medicaux
US12076234B2 (en) Stabilized fabric material for medical devices
EP4165239A1 (fr) Matériau de tissu stabilisé pour dispositifs médicaux
US11654023B2 (en) Covered prosthetic heart valve
US11013600B2 (en) Covered prosthetic heart valve
KR102683120B1 (ko) 인공 심장 판막용 밀봉 부재
KR20220163239A (ko) 인공 심장 판막용 다층 커버링
US20240099832A1 (en) Prosthetic Leaflets for Valve Replacement
EP4164551A1 (fr) Matériau textile pour dispositifs médicaux
CN118178052B (zh) 一种促内皮化覆膜瓣膜夹
US20240033079A1 (en) Implantable medical devices
US20240173126A1 (en) Textiles and medical devices using the same

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230530

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)